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Abstract    
 
Cytomegaloviruses (CMV), the prototypical β-herpesviruses, have co-evolved with their 
hosts and thus acquired multiple strategies for modulation of the immune response. Viral 
engagement of pattern recognition receptors (PRR), such as toll-like receptors (TLRs) 
and cytosolic nucleic acids sensors, initiates the host immune response through 
activation of elaborate signalling programs. The ensui g inflammatory response is 
further sustained and amplified through cytokines, such as IL-1β, activating signalling 
pathways greatly overlapping those utilized by TLRs. The central hypothesis of this 
thesis is that a viral counter-measure by murine CMV (MCMV) involves specific 
targeting of TLR- and IL-1β-induced signalling along the MyD88 to NF-κB pathway. 
To test this hypothesis MCMV inhibition of IL-1β signalling was initially investigated in 
a fibroblast cell line. It was demonstrated that in MCMV infected cells IL-1β-induced   
IκBα degradation is largely inhibited. Comparison of productive and non-productive 
infection showed this modulation requires de-novo viral gene expression beyond the 
immediate early region. Further investigations utilising a ORF M45 deletion mutant 
identified viral gene M45 as necessary for mediating he observed modulation of IL-1β-
induced IκBα degradation. To further test the hypothesis, studies were extended to 
include TLR stimulation in the context of bone marrow-derived macrophages (BMDM) 
infection. It was found that TLR7/9-induced NF-κB activation is inhibited in MCMV 
infected BMDM. Overall, data presented in this study emonstrate a previously 
unrecognised MCMV inhibition of IL-1β- and TLR7/9-induced NF-κB activation, and 
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1.1 Family Herpesviridae: A brief overview  
 
Herpesviridae is a large family of viruses, with over 200 members identified thus far, 
highly disseminated in nature. Inclusion in the family Herpesviridae has been 
historically based on virion architecture consisting of: a linear double-stranded DNA 
(varying in length from 124 to 230 kb), icosahedral c psid (approximately 125 nm in 
diameter), tegument (amorphous, sometime asymmetric material surrounding the capsid) 
and an envelope. Members of this family share four key biological properties: 
a) Their genome encodes enzymes involved in nucleic acid metabolism, DNA 
synthesis and protein processing. 
b) DNA replication as well as capsid assembly takes place in the nucleus.  
c) Lytic infection results in destruction of the infected cells. 
d) Establishment of latency following primary infection of the natural host. 
 
The family Herpesviridae is further divided into three subfamilies, alpha/beta/gamma- 






Table 1.1: Biological characteristics of the three subfamilies of 
herpesviruses * 
 
* Adapted from: (James H. Strauss, 2008) (Philip E. Pellett, 2006) 
** For each virus both the official designation (HHV = Human herpes virus + number) 





Characteristic  Alphaherpesvirinae  Betaherpesvirinae Gammaherpesvirinae* 




Short Long Relatively long 
Infection in cell 
culture 
Spreads rapidly, 
Infects many cell 
types 
Progresses slowly 
Infects primarily        
lymphoblastoid cells 
Cytotoxicity  
Much cell destruction Enlarged cells form 
Some lytic infections of 
the epithelial and 
fibroblasts cells 
Latency  
Primarily in sensory 
cells 




cells, kidneys, and 
others 





-- HHV-1 (Herpes 
simplex virus 1 (HSV-
1)) 
-- HHV-2 (Herpes 
simplex virus 2 (HSV-
2)) 
-- HHV-3 (Varicella-





-- HHV-4 (Epstein-Barr 
virus (EBV)) 





1.2 Cytomegaloviruses (CMVs) 
 
1.2.1 Human CMV (HCMV) overview and pathogenesis  
 
HCMV, a characteristic betaherpesvirus, is ubiquitously present in the human 
population. Overall prevalence of infection, however, varies greatly in accordance with 
socioeconomic circumstances. Worldwide prevalence of HCMV among women of child 
bearing age varies from 45 to 100% (Cannon et al., 2010). Horizontal transmission of 
the virus occurs via direct contact with bodily secretions such as blood, saliva and urine, 
semen and cervical secretions, and as a result of solid-organ transplantation or 
haematopoietic stem-cell transplantation. Additionally, HCMV can also be vertically 
transmitted from mother to fetus or new born (Gandhi and Khanna, 2004). Primary 
infection of an immunocompetent host is usually asymptomatic, however, may present 
clinically as mononucleosis syndrome with persistent fever, myalgia, and cervical 
adenopathy (Gandhi and Khanna, 2004). Importantly, fo lowing the resolution of acute 
infection life-long viral latency is established. Reactivation from latency under 
conditions of immunosuppression (for example following organ transplant) or 
immunodeficiency (as in the case of acquired immune deficiency syndrome (AIDS) 
patients) is a major contributor to HCMV-related disease burden. As a result, much 
research effort is directed at understanding latency i luding identification of cells 
serving as latent virus reservoirs, mapping latency at a molecular level, understanding 
the factors (at the cellular and immune system level) that maintain latency or promote 
reactivation (Mocarski, 2006) (Reddehase et al., 2002). In contrast to immunocompetent 
hosts, primary infection or reactivation in immunocompromised individuals can result in 
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serious morbidity or death. Manifestation of HCMV-associated disease differs and 
depends on the particular clinical setting. Pneumonitis and gastrointestinal disease are 
the most common complications of cytomegalovirus infection following haematopoietic 
stem-cell transplantation. In solid-organ transplant recipients HCMV-related morbidity 
can be caused by (a) an acute, systemic, febrile illn ss (sometimes referred to as CMV 
syndrome), (b) effects on specific organs, or (c) indirect effects including graft rejection, 
accelerated coronary artery atherosclerosis (heart transplant) and enhanced susceptibility 
to other opportunistic infections. In the case of AIDS patients the most frequent clinical 
manifestation of HCMV disease is retinitis. HCMV has also been suspected of 
accelerating the time to AIDS and death in patients with Human Immunodeficiency 
Virus (HIV) infection (Mocarski, 2006). Additional substantial and severe disease 
burden is caused by congenital HCMV infection. Congenital HCMV infection is 
symptomatic in about 5% to 10% of newborns of which about 10% suffer from severe 
and even fatal disease. Moreover, congenital CMV infection results in damage to the 
central nervous system (CNS) and organs of perception in 50% to 90% of symptomatic 
newborns. Importantly, CNS sequelae, mainly hearing loss, also develops in 7% to 25% 
of infants who are asymptomatic at birth (Pass, 2001). Finally, a correlation between 
HCMV and diseases such as immunosenescence and athrosclerosis has been suggested, 
however more research is required to establish the role, if any, of the virus in the 






1.2.2 Murine CMV (MCMV) as a model for HCMV 
 
Experimental studies of HCMV pathogenesis are limited by the strict species specificity 
of the virus. Despite considerable evolutionary divergence within the betaherpesvirinae 
family, MCMV has proven an invaluable model for the study of HCMV (McGeoch et 
al., 2006) (Mocarski, 2004). MCMV and HCMV share roughly 80 homologous open 
reading frames (ORFs), about half of the estimated number of ORFs encoded by these 
viruses. Approximately 40 of these are conserved across the herpesvirus family 
(Brocchieri et al., 2005) (Rawlinson et al., 1996). More importantly, pathogenesis of 
MCMV infection of mice resembles that of HCMV in its natural host (Krmpotic et al., 
2003) (Price and Olver, 1996) (Scalzo et al., 2007). Therefore, this model system allows 
the of study virus/host interactions in a physiologically relevant context. However, it is 
important to consider that conserved viral strategies for modulation of host response 
may be mediated by different viral products of the wo viruses as well as differ in 
underlying mechanisms (Mocarski, 2004).  
 
1.2.3 HCMV and MCMV virion structure and replication  
 
Key features of HCMV and MCMV virion structure and replication are shared across 
the herpesvirus family. The following overview focuses on HCMV however the 






1.2.3.1 Virion structure  
 
As mentioned above herpesviruses all share a characteristic virion structure. The 
approximately 235 kbp, double-stranded DNA genome of HCMV is packaged in a linear 
form within a 125 nm icosahedral nucleocapsid (Mocarski, 2006). The nucleocapsid is 
embedded within a protein matrix termed the tegument. Upon infection tegument 
proteins are released into the cytoplasm of the infcted cell and play a role in multiple 
viral processes including delivery of viral genomes to the nucleus, regulation of gene 
expression and modulation of host immune responses (Kalejta, 2008). Finally, the 
nucleocapsid and tegument are engulfed by a lipid bilayer envelope, derived from 
cellular membranes, containing virus-encoded glycoproteins (Mocarski, 2006). HCMV 
particles have also been shown to contain cellular and viral RNA (Bresnahan and Shenk, 
2000) (Terhune et al., 2004). The overall size of the HCMV virion is 200 to 300 nm in 
















Figure 1.1: The CMV virion. A schematic representation (not to scale) of an 
average CMV virion.  
 
 
1.2.3.2 Replication  
 
For the purposes of this overview the replication cycle will be divided into following 
steps: a) attachment and entry, b) gene expression and DNA replication, c) capsid 






























Figure 1.2: A schematic representation of key featu res of CMV replication.  
The virus enters the cell via direct fusion of viral envelope and cellular plasma 
membrane leading to the release of nucleocapsid and tegument proteins into the 
cytoplasm. The capsid is then shuttled, along microtubules, to the nuclear pore 
complex and viral DNA is delivered into the nucleus. Transcription of viral genes 
begins immediately with immediate-early (IE) genes are transcribed first, 
followed by early (E, also called delayed-early) genes and finally late (L) genes 
(cytoplasmic translation is not depicted). Viral DNA is replicated and 
encapsidated in the nucleus. Initially a procapsid shell is formed to which 
genome-length segment of viral DNA is inserted to produce a filled 
nucleocapsid. Nucleocapsids egress from the nucleus through sequential 
budding and fusion with the inner and outer nucleic membranes, respectively 
(not depicted). This results in non-enveloped nucleocapsids in the cytoplasm 
which then re-enveloped as they bud into Golgi apparatus-derived vesicles 
containing viral glycoproteins. A cellular vesicle engulfing a fully formed virion is 
thus formed. Release of the virion is completed through shuttle of the virion-
containing vesicle to the cell surface followed by fusion of vesicle and plasma 
membranes. This resulted in the release of a mature virion from the cell 
(variation in capsid or virion sizes appearing in the figure are due to presentation 




Attachment and Entry  
 
Herpesviruses enter the cell via direct fusion of viral envelope and cellular plasma 
membrane. In the case of HCMV this process is mediat  by binding of viral envelope 
glycoproteins to cell surface receptors. This allows the fusion of viral and cellular 
membranes resulting in introduction of the nucleocapsid and tegument proteins into the 
cytoplasm. The following model has been suggested for HCMV entry into fibroblasts: 1) 
An initial tethering step of the virion to the cell surface involves interaction of viral 
homodimers of glycoprotein (g)B (a dimer this complex is referred to as gB) and 
heterodimers of gM:gN with cellular heparan sulfate proteoglycans (HSPGs). 2) A more 
stable binding step follows, probably mediated by gB through interaction with an 
unidentified cellular receptor.  3) Fusion of viral and cellular membranes is mediated by 
a gH:gL:gO complex along with gB. Cellular integrin heterodimers (α2β1, α6β1, αVβ3) 
are thought to play a role in both binding and binding/fusion steps of viral entry in a 
manner depending on gB and gH (Isaacson et al., 2008). Homologous glycoproteins of 
MCMV have not been investigated with respect to their role in viral attachment and 
entry. The exception being the positional homolog of HCMV gO, m74 of MCMV, 
which has recently been shown to function similarly to its HCMV counterpart (Scrivano 
et al., 2010). HCMV has also been shown to enter specific cells types, such as 
endothelial and epithelial cells, via endocytosis (Bodaghi et al., 1999) (Ryckman et al., 





Gene expression and DNA replication 
 
Following fusion of virion and cell membranes the capsid and tegument proteins are 
directly released into the cytoplasm. The capsid is then shuttled, likely assisted by 
tegument proteins, along microtubules to the nuclear pore complex. Viral DNA is then 
delivered into the nucleus and transcription begins (Kalejta, 2008). CMVs gene 
transcription occurs in a cascading manner such that immediate-early (IE or α) genes are 
transcribed first, followed by early (E, also called delayed-early or β) genes and finally 
late (L or γ) genes (Mocarski, 2006). IE genes are expressed immediately upon entry, 
independently of de novo synthesis of viral proteins a d function in regulating further 
viral gene transcription. The major IE gene regions f HCMV and MCMV are highly 
similar. A complex regulatory sequence- the major IE enhancer promoter (MIEP) - 
controls the transcription of major IE transcripts. Located down-stream of MIEP is a 
transcriptional unit which gives rise to the alternatively spliced ie1 and ie2 or ie1 and ie3 
transcripts in HCMV and MCMV, respectively. The MCMV major immediate-early 
region also includes an ie2 gene positioned on the opposite side of the enhancer 
elements and transcribed in the opposite direction in relation to the ie1/ie3 genes (it 
should not be confused with the HCMV ie2 which is the functional homologue of 
MCMV ie3) (Busche et al., 2008). Early gene expression requires prior expression of IE 
functional proteins.  Early gene products play a role in diverse processes including viral 
DNA synthesis and capsid maturation as well as altering host cell and host animal 
response to infection. L genes are expressed last and c n be further subdivided into γ1
(or leaky L) genes, when expression begins after 24 hpi and is resistant to inhibition of 
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DNA synthesis, and γ2 genes (or true L), when expression is dependent on viral DNA 
synthesis. Early and late gene products contribute to capsid maturation, DNA 
encapsidation, virion maturation, and egress from the cell (Mocarski, 2006).  
 
Capsid assembly egress and release 
 
Viral DNA is replicated and encapsidated in the nucle s. Initially a procapsid shell is 
formed to which genome-length segment of viral DNA is inserted to produce a filled 
nucleocapsid, the DNA entry portal is then covered by portal capping protein (PCP, 
encoded by UL75). Nucleocapsids egress and release from the nucleus and cell is a 
complex process. Initially nucleocapsids undergo envelopment by budding through the 
inner nuclear membrane. It is thought that this is followed by fusion with the outer 
nuclear membrane results in deenvelopment and release of nucleocapsids into the 
cytoplasm. Nucleocapsids are then re-enveloped as they bud into Golgi apparatus-
derived vesicles containing viral glycoproteins. A cellular vesicle engulfing a fully 
formed virion is thus formed. Release of the virion s completed through shuttle of the 
virion-containing vesicle to the cell surface followed by fusion of vesicle and plasma 
membranes. This results in the release of a mature virion from the cell (Mettenleiter et 
al., 2009).  
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1.3 Pattern recognition receptors and sensing of CM V  
 
Innate immune recognition of pathogens is mediated by germline encoded receptors 
which detect conserved and invariant features of microorganisms. These receptors are 
known as pattern recognition receptors (PRRs). Their targets are often referred to as 
pathogen-associated molecular patterns (PAMPs) although they may be equally present 
on non-pathogenic microorganisms. Sensing of pathogens via PRRs initiates innate 
immune activation as well as stimulates and regulates the adaptive immune response 
(Janeway and Medzhitov, 2002) (Medzhitov, 2007). PRRs, namely members of the Toll-
like receptor (TLR) family, Absent in melnoma 2 (AIM2) and DNA-dependent activator 
of IFN-regulatory factors (DAI), shown to play a role in HCMV/MCMV detection are 
discussed below. 
 
1.3.1 Toll-like receptors- overview and role in CMV detection 
 
1.3.1.1 Toll-like receptors- overview  
 
TLRs are type I integral membrane glycoproteins with an extracellular leucine-rich 
repeat domain (LRR) and a cytoplasmic region, conserved also in interleukin-1 receptors 
(IL-1Rs), known as a Toll/IL (interleukin)-1 (TIR) domain (Akira and Takeda, 2004). 
To date 10 TLRs are known in humans while 13 TLRs have been identified in mice, 
although mouse TLR10 is not functional. TLR1-9 are conserved between both species. 
Collectively TLRs have been shown to detect PAMPs from bacteria, viruses, parasites 
and fungi (see summary in Table 1.2) (Kawai and Akira, 2010). TLRs are presents both 
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on the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6, TLR11) as well in endosomal 
compartments (TLR3, TLR7-10) (Takeuchi and Akira, 2010).  
 
Table 1.2: TLRs and their Ligands (adapted from (Ta keuchi and Akira, 
2010)) 
TLR Ligand  Origin of the Ligand  
TLR1 Traicyl lipoprotein  Bacteria  
TLR2  Lipoprotein  Bacteria, viruses, parasites, self  
TLR3  dsRNA Viruses 
TLR4  LPS Bacteria,  
TLR5  Flagellin Bacteria 
TLR6  Diacyl lipoprotein Bacteria, viruses 
TLR7 (human 
TLR8)  
ssRNA Viruses, bacteria, self 
TLR9  CpG-DNA Viruses, bacteria, protozoa, self 
TLR10 Unknown Unknown 
TLR11 Profilin-like molecule  Protozoa 
 
1.3.1.2 TLR induced responses  
 
TLR engagement by their cognate PAMPs leads to activation of nuclear factor -κB (NF-
κB) and mitogen-activated protein kinases (MAPKs) resulting in the secretion of 
inflammatory cytokines. In addition, secretion of type I interferons (IFN) is stimulated in 
a TLR and cell specific manner (Figure 1.3) (Kawai and Akira, 2011). TLRs signal via 
their cytoplasmic TIR domain which mediates the recruitment of TIR-domain-
containing adaptor proteins (i.e., myeloid differentiation primary response protein 88 
(MyD88), TIR domain-containing adaptor inducing IFN-β (TRIF), TIR domain-
containing adapter protein (TIRAP, also known as MAL), TRIF-related adaptor 
molecule (TRAM)). TLR signalling is often divided into MyD88-dependent and TRIF-
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dependent signalling cascades (O'Neill and Bowie, 2007). All TLRs, except TLR3, 
require MyD88 for signal transduction i.e. signal in a MyD88-dependent way. MyD88-
mediated signalling culminates in NF-κB and MAPKs activation and induction of 
inflammatory cytokines (Kawai and Akira, 2011). This pathway, which is investigated 
in this thesis in the context of viral infection, is described in some detail in the next 
section. In addition, TLR2, TLR7 and TLR9 activate MyD88-dependent, but distinct 
pathways, to induce type I IFN secretion. Induction of type I IFN responses is cell type 
restricted. To date TLR7/TLR9 and TLR2 have been shown induce an IFN response in 
plasmacytoid dendritic cells (pDC) and inflammatory monocytes (iMO), respectively 
(Barbalat et al., 2009) (Gilliet et al., 2008). TRIF-mediated signalling is induced by 
TLR3 and TLR4 (TLR4 uniquely utilises both MyD88 and TRIF-dependent signalling). 
Recruitment of TRIF leads to activation of both interferon regulatory factor 3 (IRF3) and 
NF-κB. Thus inducing the expression of both inflammatory cytokines and type I IFN 
(Kawai and Akira, 2010).  
 
Despite great overlap in signalling pathways and transcriptional responses induced by 
different TLRs, it is thought that the generation of a pathogen tailored response is 
enabled by multiple mechanisms including: - Selectiv  recruitment of one or more TIR-
domain-containing adaptor proteins; - Cell type specific signalling at least partially due 
to differential expression patterns of TLR as well as signalling modules utilised by them; 
- Intracellular translocation of TLRs following ligand binding resulting in initiation of 
distinct signalling pathways or differential response kinetics; - Crosstalk within the TLR 
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Figure 1.3: TLR induced responses . TLR engagement by their cognate 
PAMPs leads to recruitment of TIR-domain-containing adaptor proteins: MyD88, 
TRIF, TIRAP (MAL) and TRAM. All TLRs, except TLR3, signal in a MyD88-
dependent way which culminates in NF-κB and MAPKs activation and thus 
induction of inflammatory cytokines. Stimulation of TLR2, TLR7 and TLR9 
additionally results in secretion of type I IFN. This response is cell type 
restricted- TLR7/TLR9 and TLR2 induce an IFN response in plasmacytoid 
dendritic cells (pDC) and inflammatory monocytes (iMO), respectively. TLR4, 
expressed at the cell surface, initially signals in a TIRAP/MyD88 to induce 
inflammatory cytokines. It is then translocated into phagosomes where it recruits 
signal adaptors TRAM/TRIF resulting in upregulation of both inflammatory 
cytokines and type I IFN. TLR3 signals exclusively via TRIF to induce both 
inflammatory cytokine and type I IFN responses (figure is based on (Kawai and 








1.3.1.3 MyD88-dependent activation of NF-κB and MAPKs 
 
Engagement of all TLRs (except TLR3) by their cognate PAMPs leads to direct or 
adaptor-protein mediated binding of MyD88. MyD88 serves as a recruitment platform 
for IL-1R associated kinase 4 (IRAK) followed by IRAK2 and IRAK1 (Kawai and 
Akira, 2010). Activation of IRAK4 is necessary for NF-κB and MAPK activation, while 
IRAK1 and IRAK2 are required for the initiation of a robust and sustained TLR 
response (Suzuki et al., 2002) (Kawagoe et al., 2008). IRAKs form a family of 
serine/threonine kinases however the exact role of their kinase activity in the context of 
TLR signalling is complex. Phosphorylation of IRAK1, and possibly IRAK2, results in 
their dissociation from the receptor complex and subsequent binding to TRAF6 
(Flannery and Bowie, 2010). TRAF6 is a ubiquitin E3ligase which, together with the 
ubiquitin E2 complex Ubc13/Uev1A, synthesises K63 polyubiquitin chains (Cao et al., 
1996) (Deng et al., 2000) (Lomaga et al., 1999) (for overviews of ubiquitination see  
(Liu and Chen, 2011) (Carpenter and O'Neill, 2009)). This leads to binding and 
activation of a preformed complex consisting of thekinase TGF-β-activated kinase 1 
(TAK1) and adaptor proteins TAK1-binding protein 1 (TAB1), TAB2 or TAB3 (Wang 
et al., 2001) (Liu and Chen, 2011). This is followed by TAK1 activation of the IκB 
kinase (IKK) complex (through phosphorylation of its IKKβ subunit) resulting in NF-κB 
activation (see below). Several proteins have been shown to be poly-ubiquitinated by 
TRAF6 including TRAF6 itself, IRAK1, IRAK2, TAK1, TAB2 and NEMO. TAB2 and 
TAB3 contain an ubiquitin binding domain (UBD), whic  preferentially binds K63 
polyubiquitin chains. This binding promotes the autophosphorylation and therefore 
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activation of TAK1 (Liu and Chen, 2011). However, the exact manner in which K63 
polyubiquitin chains regulate TRAF6-TAK1-NEMO interactions is not fully understood 
(Liu and Chen, 2011). TAK1 also functions initiate a MAPKs activation cascade. It 
phosphorylates MAPK kinases which in turn phosphorylate and activate the MAPKs- 
p38 and c-Jun amino (N)-terminal kinases (JNKs). p38 and JNKs then activate various 
transcription factors and well as influence translation (Cargnello and Roux, 2011) 
(Kawai and Akira, 2010) (Figure 1.4).  
The mammalian nuclear factor-κB (NF-κB) family includes five members: RelA (p65), 
RelB and c-Rel, and the precursor proteins NF-κB1 (p105) and NF-κB2 (p100), which 
are processed into p50 and p52, respectively. NF-κB transcription factors form homo- 
and heterodimers to bind κB sites in promoters or enhancers of targets genes. 
Transcription of target genes is then regulated through the recruitment of transcriptional 
co-activators and transcriptional co-repressors (Ghosh and Hayden, 2008). The 
immediate regulatory circuit of NF-κB consists of IκB proteins and the IκB kinase 
(IKK) complex. The IKK complex is composed of two catalytically active kinases, 
IKK α and IKKβ, and the regulatory subunit IKKγ (NEMO). Under resting conditions 
members of the IκB family, namely IκBα, IκBβ and IκBε, bind and sequester NF-κB 
dimmers in the cytoplasm. Stimulation, for example by TLRs or cytokines such as 
IL-1β, leads to activation of the IKK complex which in turn phosphorylates the IκB 
proteins. This targets IκB proteins for ubiquitination and proteasomal degradation thus 
releasing NF-κB dimers for nuclear translocation. IKKβ and IKKγ dependent activation 






































Figure 1.4:  MyD88-dependent activation of NF- κB and MAPKs. TLR ligation 
leads to direct or adaptor-protein mediated binding of MyD88 which serves as a 
recruitment platform for IRAK4, IRAK2 and IRAK1. Subsequently IRAK1and 
IRAK2 dissociate from the receptor complex and bind to TRAF6. Next a 
preformed complex consisting of the TAK1 and adaptor proteins TAB1and TAB2 
or TAB3 is recruited. This results in activation of the kinase function of TAK1 
which phosphorylates IKKβ and thus activates the IKK complex and 
subsequently NF-κB. NF-κB translocates to the nucleus where it upregulates the 
expression of cytokine genes. TAK1 also functions to initiate MAPKs activation 
cascades leading to further transcription-factor activation. 
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1.3.1.4 TLRs in CMV detection 
 
Liver transplant patients with a TLR2 polymorphism, which in-vitro shows impaired 
recognition of viral-envelope protein gB, exhibited significantly higher viral load and 
increased susceptibility to HCMV disease (Brown et al., 2009) (Kijpittayarit et al., 
2007). These findings corroborate earlier studies which suggested that TLR2, probably 
acting as a heterodimer with TLR1, recognises HCMV resulting in NF-κB activation and 
cytokine secretion. TLR2 activation by the virus was ttributed to recognition of 
envelope proteins gH and gB (Compton et al., 2003) (Boehme et al., 2006). Earlier 
studies on the role of TLR2 in MCMV biology failed to detect a difference in viral load 
in the spleen and it was reported, although the data was not provided, that TLR2 
deficiency did not affect mouse resistance to infection (Delale et al., 2005). However, 
Szomolanyi-Tsuda et al found significantly increased viral load in spleen and liver of 
TLR2 knock-out mice in comparison to wild type animals. Elevated viral load correlated 
with reduced cytokine expression and a decrease in numbers of NK cells, but normal 
functionality, in the organs examined (Szomolanyi-Tsuda et al., 2006). Interestingly, 
pro-inflammatory cytokine secretion by macrophages and DCs in response to MCMV 
infection was shown to depend on TLR2 (Barbalat et al., 2009) (Compton et al., 2003). 
Moreover, TLR2 recognition of MCMV contributed to type I IFN secretion from pDCs 
(Barbalat et al., 2009).   
 
MCMV systemic infection of TLR9 knock-out (TLR9-/-) animals or mice lacking a 
functional TLR9 receptor results in increased mortality and elevated viral titres in the 
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spleen in comparison to wild type animals. In TLR9-/- animals an impaired cytokine 
response to infection was observed (variation regarding the effect on specific cytokines 
exists between reports, possibly due to differences in the genetic background of animals 
used). This correlated with diminished activation of NK cells (key effector cells in 
innate immunity to CMV (Stipan Jonjic, 2006)) in the absence of TLR9 (Delale et al., 
2005) (Krug et al., 2004) (Tabeta et al., 2004). Importantly, TLR9, but not MyD88, was 
found redundant for anti-viral defence in the liver. Cytokine production (including 
IFNα) as well as NK cells and macrophage accumulation in the liver were un-affected in 
TLR9-/- mice. Moreover, viral replication and general virus-induced liver disease were 
comparable to wild type animals. This was in contrast to finding in spleen suggesting a 
site specific contribution of TLR9 to localised response to MCMV infection (Hokeness-
Antonelli et al., 2007). TLR7 was also found to play a role in host immunity to MCMV. 
Zucchini et al found higher susceptibility to MCMV-induced death, increased viral load 
in the spleen and significantly lower serum levels of IFNα in TLR9-/-TLR7-/- in 
comparison to TLR9 or TLR7 only knock-out animals. Indeed, the phenotype of TLR9-
/-TLR7-/- animals with regards to susceptibility to MCMV-induced death recapitulated 
that of MyD88-/- mice. Thus, suggesting an overlapping function for TLR7 and TLR9 
detection of MCMV in host response to infection (Zucchini et al., 2008). It is important 
to note that while a role for TLR9 and TLR7 in MCMV detection has been demonstrated 
it is not clear exactly which viral determinants are sensed or what is the mechanism 
responsible for delivering them into the endosomal compartment in which these TLRs 
reside (Rathinam and Fitzgerald, 2011).  
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Finally, TLR3 was found to contribute to the innate immune response to MCMV. Tabeta 
et al found that in comparison to wild type mice infection of TLR3-/- results in a highly 
significant increase in viral titres in the spleen and reduced systemic levels of cytokines 
including type I IFN (Tabeta et al., 2004). Although a study by Delale et al failed to find 
a role for TLR3 in host response to MCMV (Delale et al., 2005).  
 
1.3.2 AIM2 - overview and role in CMV detection 
 
AIM2, a member of the pyrin and NIH domain-containing protein family (PYHIN 
family), is a cytosolic dsDNA sensor (Schattgen and Fitzgerald, 2011) (Paludan et al., 
2011). Following binding of dsDNA AIM2 initiates the formation of inflammasomes - 
intracellular multiprotein complexes responsible for cleavage of pro-IL 1β and pro IL-18 
into active IL-1β and IL-18, respectively (Rathinam and Fitzgerald, 2010). A role for 
AIM2 in innate immune sensing of MCMV was demonstrated by Rathinam et al 
(Rathinam et al., 2010). This study found that in comparison to control animals MCMV-
infected AIM2-deficient mice exhibited reduced levels of serum IL-18 and lower spleen 
IFNγ production as well as elevated viral loads in thisorgan (Rathinam et al., 2010).  
 
1.3.3 DAI - overview and role in CMV detection 
 
 DAI (also known as ZBP1 or DLM-1) is a cytoplasmic DNA sensor. It activates the 
interferon regulatory factor (IRF) and NF-κB transcription factors, leading to type-I 
interferon production (Takaoka et al., 2007) (Kaiser et al., 2008) (Rebsamen et al., 
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2009). Recent studies have implicated DAI in mediating type I IFN production by 
HCMV-infected fibroblasts (DeFilippis et al., 2010a) (DeFilippis et al., 2010b).  
 
1.4 IL-1β – overview and role in CMV biology 
 
1.4.1 IL-1β overview  
 
Interleukin-1β (IL-1β) is a member of the IL-1 family (IL-1F) of immune-modulators of 
which 11 members are currently known in humans including IL-1β, IL-1α, IL-1 receptor 
antagonist (IL-1Ra), IL-18 and IL-33 (Dinarello, 2009). IL-1β and IL-1α are often 
referred to as IL-1 as both signal through the same receptor complex- IL-1 type I 
receptor (IL-1RI). However, these two cytokines differ in several ways: 1) IL-1β 
circulates systemically while IL-1α acts locally; 2) Pattern of expression- IL-1β is 
mainly produced by monocytes and macrophage while IL-1α is more widely expressed; 
3) Transcription of these two genes is differentially regulated both during development 
and in response to environmental cues; 4) IL-1α can also localise to the nucleus and act 
as a transcriptional activator (Sims and Smith, 2010). The major source of IL-1β is 
monocytes, macrophages and dendritic cells. B lymphocytes and NK cells can also 
produce this cytokine while fibroblasts and epithelial cells generally do not (Dinarello, 
2009). Multiple cell types including endothelial and epithelial cells, fibroblasts, dendritic 
cells and T lymphocytes are stimulated by IL-1β (Weber et al., 2010) (Dinarello, 1996).  
 
IL-1β is a master regulator of the inflammatory response through synergetic action with 
TNF α to activate proinflammatory responses in a wide range of cells (such as induced 
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secretion of cytokine and chemokines especially interleukin (IL)-6, increased expression 
of adhesion molecules in endothelial cells and promotion of diapedesis and the acute 
phase response (Barksby et al., 2007) (Dinarello, 2011a). The key role played by IL-1β 
in initiation and mediation of inflammation is underscored by the growing number of 
non-infectious inflammatory diseases (also known as autoinflammatory diseases) which 
are now treated as standard by blocking IL-1β function (Dinarello, 2011a) (Masters et 
al., 2009). In addition, IL-1β contributes to the shaping of adaptive immune respon es 
through direct and indirect effects on T and B cellr sponses (Dinarello, 2011b).  
  
IL-1β is produced as an inactive precursor (pro- IL-1β, 33 kDa in size) which is cleaved 
into the bioactive cytokine (17 kDa). The best understood mechanism for IL-1β 
processing is mediated by the protease caspase-1 in the context of multimeric protein 
platforms called inflammasomes. Inflammasomes are categorised by the PRR that 
initiates their formation. To date, four inflammasome complexes have been defined. 
Three are assembled upon activation of NLRP1, NLRP3 and IPAF- members of the 
nucleotide-binding domain leucine-rich repeats (NLRs) family of PRRs. The forth 
inflammasome is recruited to AIM2, a member of the pyrin and NIH domain-containing 
protein family (PYHIN family), which senses dsDNA in the cytoplasm (Bauernfeind et 
al., 2011). The AIM2 inflammasome is described below as AIM2 has been shown to 
play a role in host response to MCMV (Rathinam et al., 2010). Similar principles apply 
to the other inflammasomes. Following binding of dsDNA AIM2 engages the apoptosis-
associated speck-like protein containing a CARD (ASC) protein. This allows for the 
recruitment of pro-caspase-1 and the production of active caspase-1. Caspase-1 then 
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cleaves pro- IL-1β into active IL-1β (Bauernfeind et al., 2011). Alternative, caspase-1 
independent, IL-1β processing mechanisms exist including neutrophil-derived serine 
proteases or proteases released from microbial pathogens (Netea et al., 2010). Finally, 
IL-1β is secreted via an unknown mechanism (Sims and Smith, 2010).  
 
IL-1β signals through a receptor heterodimer composed of IL-1 receptor type I (IL-1R1) 
and IL-1R accessory protein (IL-1RAP). IL-1β initially binds to IL-1R1 followed by 
IL-1RAP recruitment. Both receptor sub-units have extracellular immunoglobulin 
domains and a TIR domain in the cytoplasmic portion (O'Neill, 2008). Formation of the 
receptor heterodimer allows for recruitment MyD88. The ensuing signalling cascade 
greatly overlaps MyD88-dependent TLR signal transduction as described in section 
1.3.1.3 (O'Neill, 2008). In brief MyD88 mediated the recruitment of IRAKs and TRAF6 
leading to activation of the IKK complex followed by activation of NF-κB and MAPK 
pathways.   
 
1.4.2 IL-1β role in CMV biology  
 
Monocytes, a major source of IL-1β, have been shown in-vitro (using isolated peripheral 
blood monocytes) to secrete IL-1β in response to HCMV infection (Dudding et al., 
1989) (Yurochko and Huang, 1999). Additionally, IL-1β has been shown to inhibit the 
growth of HCMV in primary fibroblasts and marrow stromal cell lines (Iwata et al., 
1999) (Randolph-Habecker et al., 2002). End-point assay of viral replication in primary 
fibroblasts similarly found IL-1β to inhibit MCMV growth (van der Meer et al., 1989). 
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In-vivo administration of IL-1R1, thus blocking both IL-1α and IL-1β signalling via the 
endogenous receptor, resulted in an initial trend towards increased virus titres but 
decreased titres at later time-points in both C57BL/6 and BALB/c mice (Yerkovich et 
al., 1997). In a different study, a single administration of recombinant IL-1β prior to 
infection with MCMV, did not alter survival (van der Meer et al., 1989). Interestingly, in 
an in-vivo study of serum cytokine levels following MCMV infection of C57BL/6 mice, 
no IL-1β was detected while IL-1α levels were elevated in infected animals in 
comparison to controls (Ruzek et al., 1997). A better understanding of the role IL-1β 
plays during MCMV infection awaits an examination in IL-1β knock-out animals.  
 
1.5 Crosstalk between TLRs, IL-1 β and inflammasomes  
 
TLRs and the IL-1β receptor (IL-1RI) sub-units ((IL-1R1) and (IL-1RAP)) are members 
of the  interleukin-1 receptor/Toll-like receptor superfamily (O'Neill, 2008). A 
conserved Toll/IL (interleukin)-1 (TIR) domain is present in the cytoplasmic end of both 
TLRs and IL-1RI subunits. Following ligand binding these TIR domains allow for 
recruitment of TIR-domain-containing cellular signalling adaptors (i.e. MyD88, TRIF, 
TIRAP (MAL) and TRAM) and initiation of signalling. Thus, IL-1RI and TLRs activate 
many overlapping signal transduction events (O'Neill, 2008). Importantly, TLR 
activation induces the expression of pro-IL-1β which, following independent 
inflammasome activation, is processed and secreted. S creted IL-1β goes on to activate, 
both locally and systemically, similar signalling pathways to those initially induced by 
TLRs. This can be viewed as a system for signal amplification (locally) and 
broadcasting (systemically or otherwise activation f cells not directly exposed to 
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microbial products). The requirement for inflammasome activation, for IL-1β 
processing, integrates signals for inflammasome-forming PRRs (Figure 1.5) (Barton, 







































Figure 1.5: Crosstalk between TLRs, IL-1 β and inflammasomes. TLRs and 
IL-1β activate many of the same signal transduction events. TLR activation 
induces the expression of pro-IL-1β which, following independent inflammasome 
activation, is processed and secreted. Secreted IL-1β goes on to activate, both 
locally and systemically, similar signalling pathways to those initially induced by 







1.6 Thesis rationale and central hypothesis  
 
Viral engagement of pattern recognition receptors, such as TLRs and cytosolic nucleic 
acid sensors, initiates the host immune response throug  activation of elaborate 
signalling programs. The ensuing response is further sustained and amplified through 
cytokines such as IL-1β activating signalling pathways greatly overlapping those utilized 
by TLRs. Several TLRs detect MCMV and play an important role in host immunity to 
this pathogen. These include TLR9, TLR7 and TLR2, which signal in a MyD88-
dependent manner resulting in NF-κB and MAPKs activation. The pro-inflammatory 
cytokine IL-1β also activates this MyD88 to NF-κB and MAPKs axis. CMVs are known 
for the multiple mechanisms by which they evade andmodulate the host immune-
response to infection (Mocarski, 2002) (Loewendorf and Benedict, 2010). It would 
therefore be anticipated that CMVs modulate TLR/ IL-1β activation of NF-κB and 
MAPK responses.  
The central hypothesis of this thesis is that a virl counter-measure by MCMV involves 
specific targeting of TLR- and IL-1β-induced signalling along the MyD88 to NF-κB 
pathway.   
The main objectives of the study are: 
a) Determine whether MCMV modulates IL-1β induced NF-κB activation, more 
specifically the degradation of IκBα – the quintessential NF-κB inhibitor (Chapter 3).  
b) Identify the viral product/s mediating the modulation of IL-1β induced IκBα 
degradation (Chapter 4). 
c) Extend studies to include members of the TLR family (Chapter 5) 
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2 Chapter 2 
 
Materials and Methods 
 
2.1 Cell culture  
 
2.1.1 General methods for cell culture  
 
 
All cells were maintained in humidified incubator at  5% CO2 atmosphere, 37°C. 
Tissue culture flasks and plates were obtained from Nunc (Copenhagen, Denmark). 
Cells were cultured according to sterile technique and routinely tested for Mycoplasma 
using the MycoSensorTM PCR Assay Kit (Stratagene) (testing was preformed by Alan 
Ross, Division of Pathway Medicine, The University of Edinburgh, UK).  Reagents used 
for cell culture were additionally tested for endotoxin using the The Endosafe -PTS™ 
System (Charles River) (testing was preformed by staff a  the Clinical Research Imaging 
Centre (CRIC), The University of Edinburgh, UK).  
 
2.1.2 Cell lines 
 
The murine embryonic fibroblast-derived immortalized cell line NIH/3T3 was obtained 
from American Type Culture Collection (ATCC, USA, catalogue number CRL-1658). 
The NIH/3T3-Bam25 cell line (referred to as Bam25 in this manuscript) was derived 
from NIH/3T3 cells by transfection of the pBAM25 plasmid (a plasmid containing the 
MCMV ie1 and ie3 genes) as described previously (Angulo et al., 2000). Mouse 
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embryonic fibroblasts (MEFs) P53 -/- (ATCC, catalogue number CRL2645), were 
originally derived from mouse embryos with null mutations in the p53 gene. L929 cells 
were obtained from Sigma (catalogue number 85011425). This cell line is a subclone of 
the parental strain L, which was derived from normal subcutaneous areolar and adipose 
tissue. NIH/3T3 and Bam25 cells were grown in Dulbecco's modified Eagle medium 
(DMEM) (Lonza) supplemented with 10% heat-inactivated (HI) calf serum (CS) 
(Invitrogen), 2 mM glutamine (Lonza) and 50 U of Penicillin/Streptomycin (Lonza) per 
ml. For MEFs P53 -/- HI CS was replaced with HI Fetal Bovine Serum (FBS) (Lonza). 
The L929 cell line was grown in DMEM/F-12 media with GlutaMAX (Invitrogen) 
containing 10% HI FBS and antibiotics as described above. Medium (DMEM or 
DMEM/F-12) supplemented with CS or FCS, glutamine ad Penicillin/Streptomycin is 
hereafter referred to as complete growth medium.  For isolation and culture bone 
marrow-derived macrophages (BMDM) see section 2.2. 
 
2.1.3 Serum (CS or FBS) heat inactivation  
 
Serum was thawed overnight at 4°C followed by equilibration to 37°C in a water bath. 
Heat inactivation was achieved by incubation of serum at 56°C for 30 min. Heat 
inactivated serum was then filtered using a Stericup vacuum filtration unit (Millipore) 
aliquoted and stored at -20°C. 
 




Cells at 70-80% confluence were washed once with phos ate buffered saline (PBS) and 
then incubated with trypsin/EDTA (Lonza) at room temperature until detached (the 
volume of trypsin/EDTA used dependent on the flask size). They were then mixed with 
fresh medium (1:1 ratio of trypsin/EDTA to medium) and centrifuged at ~250g for 5 
min at room-temperature. The supernatant was discared and cell pellets re-suspended in 
appropriate amount of fresh medium and re-seeded at a split ratio of 1:2 to 1:8 
depending on cell line and experimental needs. This process was repeated every 2-3 
days up to a maximum of 25-30 passages.  
 
2.1.5 Cell counting and seeding plates 
 
To count cells after trypsinization and re-suspensio  (as described in section 2.1.4), 
10 µl of cell suspension was placed onto a haemocytometer (Bright-line Hemacytometer, 
Hausser Scientific, USA) under a cover slip and viable cells counted in the central 25 
marked squares. The number or cells per ml was calculated by multiplying the number 
of cells counted by 104 (as specified for the haemocytometer used). Cell counts were 
kept between 10-90 cells. If required, a portion of cell suspension was diluted and the 
dilution factor incorporated into calculation of cell number. This process was repeated 2-
4 times for each sample and an average count was used. Counted cells were then further 
diluted as needed in medium and seeded at specific densities in different sized tissue 
culture flasks, dishes or plates (Table 2.1). 
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N/A = Non-applicable 
 
2.1.6 Cryopreservation of cells  
 
For long term storage, cells were harvested and counted as described above. This was 
followed was centrifugation of the cells and re-suspension in freezing medium (50% CS 
or FCS (as appropriate for the cell type in question), 40% DMEM and 10% dimethyl 
sulfoxide (DMSO)) adjusted so that each 1 ml aliquot contained 2-5x106 cells. Cryovials 
(Corning) containing aliquots were placed in a Nalgene Cryo 1ºC Freezing Container at 
–80°C overnight. The next day cells were transferred to liquid nitrogen storage (-170°C).   
 
2.1.7 Thawing cells from liquid nitrogen 
 
For resurrection of frozen cells from liquid nitrogen, individual vials of cells were 
thawed in a water bath at 37°C and added to 10 ml of fresh warm complete growth 
Plate type  96 well  48 well  24 well  6 well  
 
Medium volume (µl/ well) 
           --- 100 500 1000 3000 
Cells/well (seeding density) 
NIH/3T3 or 
NIH/3T3-Bam25 
1.5x104 N/A 3x104 3x105 
(MEFs) P53 -/- N/A 2x104   
BMDM  4x104 N/A 5x105 1x106 
Inoculum volume (µl/ well) 
            --- 25-30 100 250 1000 
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medium (as defined in section 2.1.2). Cells were then centrifuged at ~250g for 5 min. 
Supernatants were discarded and cell pellets re-suspended in 5 ml fresh complete growth 
medium and transferred to a 25 cm2 tissue culture flask to be propagated as described 
previously. 
 
2.1.8 Cell viability assay  
 
Cell viability assays were performed using the Cell Titer-Blue Cell Viability Assay 
(Promega) according to manufacturer’s instructions. Briefly, cells were grown in a 96 
well plate in complete growth medium (as defined in section 2.1.2) at a volume of 
100 µl/well. To assess viability 20 µl/well of Cell Titer Blue Reagent pre-adjusted to 
room temperature was added followed by 1-3 hr incubation at 5% CO2 atmosphere, 
37ºC. Finally, fluorescence measurements were taken using the POLARstar OPTIMA 
microplate Reader (BMG LabTech, UK). 
 
2.1.9 Transfection of plasmids into cells 
 
Attractene Transfection Reagent (Qiagen) was used according to manufacturer’s 
instructions for fast-forward transfection.  Briefly, 1.2 µg DNA, dissolved in Tris-EDTA 
(TE) buffer (pH 7-8), was diluted in medium without serum or antibiotics to a total 
volume of 100 µl. Attractene Transfection Reagent (4.5 µl) was added and the mixture 
incubated for 15 min at room temperature. During this time NIH/3T3 cells were 
trypsinised, counted and cell density adjusted to 1.5x105  cells/ml. In to each well of a 6 
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well plate 2 ml of cell suspension was added followed by addition of the transfection 
complexes. Cells were then incubated under normal conditions. Transfection efficiency 
was evaluated at 24 hr post transfection using GFP expression as a positive readout. 
 
2.2 Bone-Marrow-Derived Macrophages (BMDM)  
  
2.2.1 Preparation of L929 conditioned media  
 
The L929 cell line was used to produce conditioned media containing macrophage 
colony-stimulating factor-1 (CSF-1) required for differentiating bone marrow myeloid 
progenitor cells into macrophages. L929 cells were grown in a 175 cm2 flask. When 
nearly confluent, cells were harvested and passaged into thirty 175 cm2 flasks with 50 ml 
of fresh complete growth medium each (complete growth medium is defined in section 
2.1.2). Cells were then cultured for 14 days at which point the supernatant was removed, 
filtered and aliquoted into 50 ml tubes. Aliquots were stored at -20°C.  
 
2.2.2 Mouse bone marrow progenitor cell isolation and macrophage 
differentiation 
 
Bone marrow myeloid progenitor cells were extracted from mouse femurs. All animals 
were 10-12 week old male C57BL/6 mice (BRR, The University of Edinburgh, UK). 
Mice were sacrificed via cervical dislocation performed by BRR staff. Femurs were then 
extracted under sterile conditions and any excess tis ue removed. Both ends of each 
femur were then cut off and the marrow cavity flushed using a needle (27G ½inch 
needle, BD Biosciences) attached to a syringe filled with BMDM complete growth 
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medium i.e. DMEM/F-12 media with GlutaMAX (Invitrogen) containing 10% HI FBS, 
10% L929 conditioned media and 50 U of Penicillin/Streptomycin (Lonza) per ml. Cells 
were recovered into a 50 ml tube, centrifuged (~250g for 5 min) and re-suspended in 
fresh BMDM complete growth medium. Cells were then counted and seeded at 7x106 
cells/15cm dish. These precursor cells were cultured in BMDM complete growth media 
for a 7-day differentiation period into BMDM with medium replenished at days 3 and 5. 
At day 6 adherent cells were scraped in BMDM complete growth medium, centrifuged, 
counted and seeded as required (seeding densities are specified in Table 2.1). Cells were 
cultured in DMEM complete growth media overnight and used on day 7 for experiments 
or for characterisation by FACS analysis (see section 2.2.3).  
 
2.2.3 Characterisation of BMDM by FACS analysis  
 
BMDM cultures were characterised by Flow Cytometry analysis. This technique was 
used to measure the expression of cell surface protein markers CD11b (expressed by 
both monocytes and macrophages) and F4/80 (a murine macrophage restricted cell 
surface marker). 
 
For flow cytometric analysis, bone marrow progenitor cells cultured for 7 days as 
described above were washed with ice cold PBS and hrvested by scraping. The volume 
of cell suspension was adjusted to 2 ml ice cold PBS. Cells were then counted and 
aliquoted at 1 x106 cells/1.5ml tube followed by blocking in 50 µl blocking buffer (1% 
bovine serum albumin (BSA), 1 mM sodium azide, 10% normal mouse serum (Serotec) 
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in PBS) for 10min at room temperature. The following antibodies were used for cell 
staining: Allophycocyanin (APC) conjugated monoclonal rat-anti-mouse F4/80 (IgG2a, 
Caltag Laboratories) and fluorescein isothiocyanate (FITC) conjugated rat-anti-mouse 
CD11b (IgG2b, eBiosciences) or their isotype controls. Antibodies were diluted in 
FACS buffer (PBS + 1% BSA + 1 mM Sodium Azide) to final dilution of 1:200 and 50 
µl of antibody dilution was added to cells. Thirty minutes incubation in the dark was 
followed by 3 washes with ice cold PBS, centrifugation and re-suspension in 400 µl of 
cold FACS buffer. A BD FACScan™ system (Becton Dickinson), located at the CALM 
- Confocal and Advanced Light Microscopy Facility, Queens’ Medical Research 
Institute, MRC Centre for Inflammation Research, The University of Edinburgh, was 
used to perform the flow cytometric analysis of samples. Data were analyzed using 
FlowJo software (Treestar, USA). Data from a representative experiment is shown in 
Figure 2.1. Flow cytometric analysis was performed with the kind assistance of Dr 
Kevin Robertson, data analysis and was done with the kind assistance of Muhamad 






















Figure 2.1: Phenotypic characterization of BMDM by flow cytometry. 
Expression of F4/80 and CD11b was analysed: A) Dot blot showing gating of 
cells in forward scatter (FSC) and side scatter (SSC). B) Scatter plot showing 
double-staining signals for F4/80 and CD11b plotted against each other. C + D) 
Histograms of percentage enrichment of CD11b (C) or F4/80 (D) positive cells 









The parental murine cytomegalovirus (MCMV) strain is derived from bacterial artificial 
chromosome (BAC) clone pSM3fr, containing the complete MCMV genome, as 
described previously (Messerle et al., 1997) (Wagner et al., 1999). 
 
MCMVdie3 
Construction of the MCMVdie3 has been described previously (Angulo et al., 2000), in 
short: exon 5 of the ie1/ie3 gene transcription unit was deleted from the  MCMV BAC 
clone pSM3fr (for genomic map see figure 2.2). Gene xpression of this virus is limited 
to immediate-early genes ie1 and ie2, rendering the virus absolutely growth deficient 
(Angulo et al., 2000) (Lacaze et al., 2011). Replication can be rescued by growing the 




MCMV-GFP virus is the MCMVdie3 revertant virus as described previously (Angulo et 
al., 2000) (for genomic map see figure 2.2). It contains a green fluorescent protein (GFP) 
reporter gene under control of the HCMV MIEP. The GFP expression cassette is located 
in front of the ie2 gene spanning the transcription start site of this gene and disrupting its 
expression (Angulo et al., 2000) (Lacaze et al., 2011). The ie2gene has been shown to be 
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dispensable for viral growth in vitro and in vivo (Manning and Mocarski, 1988) (Cardin 












Figure 2.2: Schematic representation of the immedia te early gene coding 
region of MCMV, MCMV-GFP and MCMVdie3 viruses.  The HindIII map of the 
MCMV genome is shown at the top. The expanded map of the HindIII K and L 
fragments represents the major IE gene region of MCMV. Coding exons are 
shown in black, and the first noncoding exon of the ie1/ie3 transcription unit is 
depicted as an open rectangle. The gray box marks the MCMV enhancer ie1/ie3 
promoter. The structure of the ie1 and ie3 transcripts is indicated below line 1 of 
the expanded map. The deletion in the fifth exon of the ie3 transcript is marked 
by the delta (∆). The cross-hatched box in front of the GFP ORF represents the 





This virus is a kind gift from Professor W. Brune (Leibniz Institute for Experimental 
Virology, Hamburg, Germany) and has been previously described (Brune et al., 2003), 
in short: This virus was constructed using a BAC clone of MCMV-GFP which in turn is 
derived from the MCMV BAC plasmid pSM3fr and contais a enhanced green 
fluorescent protein (EGFP) reporter gene under control of the HCMV MIEP,  inserted 
into the MCMV ie2 locus (Brune et al., 2003) and Wolfram Brune, Personal 
communications). MCMV-GFP BAC clone has the same genomic structure as the above 
described MCMV-GFP but was constructed independently from the MCMV BAC clone 
pSM3fr and is not a MCMVdie3 revertant (Wolfram Brune, Personal communications). 
ORF M45 was deleted from the MCMV-GFP BAC and replaced with a zeocin 
resistance gene (Brune et al., 2003).  
 
CM45 (in previous publications referred to as revertant M45 (RM45))  
A kind gift from Professor W. Brune (Leibniz Institute for Experimental Virology, 
Hamburg, Germany), has been previously described (Mack et al., 2008), in short: the 
nonessential genes m02 to m06 are replaced with an M45 gene tagged with an influenza 
virus hemagglutinin (HA) epitope, under the control of a murine pgk promoter (Mack et 






2.3.2 Viral stock preparation  
 
For each virus strain a seed stock was initially produced from an existing low passage 
stock and this was used for generation of bulk stocks. NIH/3T3 cells were used for all 
viruses except MCMVdie3 for which the Bam25 complementary cell line was used. For 
preparation of bulk stock cells were infected at MOI of 0.001 in suspension (total 
volume 5 ml) for 30 min at 37°C with occasional tapping. Allowing for 4.5- 5x106 
cells/175cm2 flask cells were seeded and flasks were topped up to 20 ml with DMEM 
supplemented with 3% HI CS, glutamine and Penicillin/Streptomycin (as detailed in 
section 2.1.2). Infected cultures were grown under normal condition for 5-7 days until a 
nearly complete cytopathic effect (CPE) was observed. Supernatant and cells were 
harvested from multiple flasks and combined. When possible, viral stock was 
concentrated immediately, if this was not possible the harvested stock was aliquoted into 
50 ml tubes and these were stored at -80°C.  
 
2.3.3 Concentration of viral stocks  
 
Preferentially the procedure for viral stock concentration was performed immediately 
upon harvest. However if frozen aliquots were used then these were allowed to thaw 
gradually at room temperature for about 30min followed by incubation in a 37°C water 
bath. In order to harvest intracellular as well as extracellular virus fresh or thawed stock 
was centrifuged (7000g, 4ºC, 20 min, Sorval SLA-1500 rotor). All the following steps 
were performed on ice. Supernatant was collected into fresh centrifuge tubes and kept on 
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ice. Cell pellet was re-suspended in 10 ml ice-cold medium and homogenised using a 40 
ml homogeniser (Wheaton, USA). Disrupted cells were centrifuged in a 30 ml tube 
(3600g, 4ºC, 20 ml, SORVAL SS34 rotor) and the supernatant pulled together with total 
viral stock. This was followed by centrifugation (30,000g, 4ºC, 3 hr, SORVAL rotor 
SLA-15000). The supernatant was discarded and the virus-containing pellet was 
incubated in residual fluid overnight on ice in a cold room (4°C). The next day pellets 
were re-suspended by pipetting up and down using a 1000 µl micropipette and pooled. 
Virus suspension was then homogenised using a 25 ml ho ogeniser (Wheaton, USA) 
and gently pipetted onto a 20% sorbitol solution (sorbitol solution was prepared in Tris 
buffered saline (TBS), pH = 7.8; sorbitol was purchased from Sigma) in 30 ml 
centrifugation tubes (at a ratio of 10 parts sucrose to 1 part virus suspension). These 
were then centrifuged (30,000g, 4ºC, 3 hr, SORVAL SS34 rotor). The supernatant was 
discarded and 500 µl 3% FCS DMEM medium was added per tube followed by 2 hr 
incubation on ice and final re-suspension using 1000 µl micropipette. Total volume was 
adjusted to 3 ml and further homogenised using a 5 ml homogeniser (Wheaton, USA). 
Aliquots of 50 µl, 100 µl and 200 µl were prepared and stored at -80ºC.  
 
2.3.4 Titration of virus by plaque assay 
 
Plaque assays were used to measure the concentration of virus in a sample i.e. virus titre. 
Plaque assays were performed on MEFs P53 -/- for all viruses except MCMVdie3 in 
which case the Bam25 cell line was used. Cells were s eded in 24 or 48 well plates and 
incubated overnight at 5% CO2 atmosphere, 37°C (for seeding densities see Table 2.1). 
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On the day of the assay, 10 fold serial dilutions (u ually 10-1 to 10-6) of the virus-
containing sample were prepared in duplicate. Culture medium supplemented with 3% 
serum was used to dilute the virus. When using 48 well plates 100 µl of virus inoculum 
was transferred onto the cells, 200 µl were used for 24 well plates. This was followed by 
1h incubation at 5% CO2 atmosphere 37°C at which time the monolayer was wahed 
once with medium. To cover the cells a 0.25% agarose-medium mixture was prepared 
by: heating to boiling point pre-made 2.5% agarose solution (2.5% agarose in distilled 
water) and diluting it 1:10 in 3% serum supplemented medium. Wash medium was then 
removed from the monolayers and the agarose-medium mixture added carefully. Cells 
were then incubated for 3-4 days under normal conditions at which point plaques were 
counted. To calculate the virus titre measured in plaque forming units to ml (PFU/ml) 
the following equation was used: 
 
PFU/ml = number of plaques counted * individual dilution factor * 10 (in the case of 48 
well plates) or *5 (in the case of 24 well plates) 
 
2.3.5 Infection of cells 
 
Once the titre of a given viral stock was known it was possible to calculate the amount 
of viral stock needed to achieve a desired multiplicity of infection (MOI). The MOI 
corresponds to the number of PFUs delivered per cell. To infect cells, viral inoculum 
was prepared by mixing the required amount of viral stock with 3% serum supplemented 
media. The total volume of inoculum used for different plate formats is specified in 
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Table 2.1. Cells were incubated with the viral inoculum for an absorption period of 1 hr 
at 5% CO2 atmosphere, 37°C. Monolayers were then washed three imes with media and 
replenished with normal growth media. Time zero (T0) or zero hours post infection 
(0 hpi) corresponds to the end of the viral adsorpti n period. For mock infections the 
same medium used for preparation of viral inoculum was used only with no virus added. 
All wash steps and medium replenishing steps were followed as per infected wells.   
 
2.3.6 Viral growth curves  
 
2.3.6.1 Plaque assay based growth curves  
 
Growth curves were used to analyse viral replication. This allowed to compare the effect 
of different treatments on viral growth or to compare growth characteristics of wild type 
versus mutant viruses. To perform growth curve analysis, cells were seeded in a 24 well 
plate and incubated over night at 5% CO2 atmosphere, 37°C. The next day infection at a 
low MOI (in this study MOI of 0.2) or high MOI (in this study MOI of 2) was used. For 
infection procedure see section 2.3.5. Supernatants of cultures were sampled at 24 hr 
intervals on days 1 to 5 or 6 post infection. Collected supernatants were titrated using 
plaque assays.  
 
2.3.6.2 Fluorescence based growth curves of GFP-reporter virus 
 
Viral growth was evaluated by measuring GFP expression by the MCMV-GFP virus 
(described in section 2.3.1).To ensure that MCMV-GFP characteristics of replication 
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reflect that of the wild type virus, the growth kinetics of MCMV and MCMV-GFP were 
analysed using plaque assay based growth curves (Figure 2.3). MCMV-GFP replication 
was effectively indistinguishable from that of MCMV. This is in accordance with 
previously published data (Angulo et al., 2000). A strong correlation between GFP 
signal and PFU/ml measurements has been previously demonstrated (Dr M. Blanc, 
DPM, Personal communications). Fluorescence based growth curves were performed as 
follows: NIH/3T3 cells were seeded in black (clear bottom) 96-well plates and incubated 
overnight at 5% CO2 atmosphere, 37°C. Phenol red-free DMEM was used. The next day 
cells were infected at a MOI = 0.2. GFP signal over time was measured using a 
POLARstar OPTIMA microplate Reader (BMG LabTech, UK). Excitation and emission 




















Figure 2.3: Comparison of growth kinetics of MCMV a nd MCMV-GFP in 
NIH/3T3 cells.  NIH/3T3 cells were infected at an MOI = 0.05 with MCMV or 
MCMV-GFP. At indicated time points post infection (days post infection) 
supernatants from the infected cultures were harvested and titered on  
MEFp53 -/- monolayers. Error bars indicate the standard deviation from three 
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2.4 Cytokines and agonists  
 
Recombinant mouse IL-1β (Thermo Scientific, catalogue number RMIL1BI) and 
recombinant mouse TNFα (Thermo Scientific, catalogue number RMTNFAI) were re-
constituted in 0.5 ml dH2O and diluted in 10% FCS supplemented DMEM to a 
concentration of 1 µg/ml. Recombinant mouse IFNβ was purchased from Stratech 
Scientific (catalogue number 12400-1). Aliquots of these cytokines were kept at -80°C.  
 
TLR9 ligand ODN 1668 (InvivoGen, catalogue number tlrl-modnb) and TLR9 ligand 
control (InvivoGen, catalogue number tlrl-modnbc) were re-constituted in sterile 
endotoxin-free water, aliquoted and stored at -20°C.  
 
TLR7 ligand R-848 ((4-Amino-2-(ethoxymethyl)-a,a-dimethyl-1H-imidazo[4,5-
c]quinoline-1-ethanol, S 28463, Resiquimod), Enzo Life Sciences, catalogue number 
ALX-420-038) was re-constituted in DMSO aliquoted and stored at -20°C. 
 
2.5 Protein methods  
 
2.5.1 Buffers and solutions used for protein methods  
 
Lysis buffer: 50 mM Tris-Cl pH 7.5, 100 mM NaCl, 1% (w/v) NP40 (also known as 
IGEPAL CA-630 (Sigma)). Shortly before use the required amount of lysis buffer was 
supplemented with protease inhibitors (Roche, Complete tablets, catalogue number 04 
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693 116 001) and phosphatase inhibitors (Roche, PhosStop, catalogue number 04 906 
837 001)). 
Laemmli sample loading buffer: 2 x sample loading buffer was bought from Sigma 
(catalogue number S3401).  
Laemmli Running Buffer (Tris-Glycine): 25 mM Tris, 192mM glycine, 0.1% SDS, 
pH 8.3.  
Transfer buffer (Towbin buffer): 25 mM Tris, 192 mM glycine, 20% (v/v) methanol, 
0.025% SDS, pH 8.3. 
Tris-Buffered Saline (TBS): 10 mM Tris; 100 mM NaCl, pH 7.8. 
Tris-buffered saline- Tween (TBS-T): 10 mM Tris-HCl, 100 mM NaCl, 0.2% 
Tween-20.  
10% Ammonium Persulfate (APS): 1 gr of APS was added to 10 ml dH2O, aliquoted 
and stored at -20°C.  
1 M Tris-HCl pH 6.8: 120 g Tris were added to 800 ml of dH2O, pH was adjusted 
using HCl and total volume made up to 1 litre with dH2O.  
1.5 M Tris- HCl pH 8.8: 181 g of Tris were added to 800 ml of dH2O, pH was adjusted 
using HCl and total volume made up to 1 litre with dH2O.  
10% Sodium dodecyl sulphate (SDS): 10 g of electrophoresis-grade SDS were 







2.5.2 Preparation of protein extracts for western blot analysis 
 
Cells were washed twice with ice cold PBS before ice cold lysis buffer was added (100 
µl/well in a 24well plate; 150 µl/well in a 6 well p ate). After which cells were scraped 
off and transferred to an Eppendorf tube. Samples were then incubated on ice for 30 min 
(if required samples were then stored at -80°C for later processing). Lysates were then 
cleared by centrifugation at maximum speed in a table-top centrifuge for 5 min at 4ºC. 
Supernatants were transferred to a fresh tube and kept at -80°C until analysed. Protein 
concentration was determined using a BCA (bicinchoninic acid) Protein Assay Kit 
(Thermo Scientific Pierce, catalogue number 23228).  
 
2.5.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blot analysis  
 
Following determination of protein concentration, a equal amount of total protein from 
each sample (typically 5-8 µg) was mixed with 2x Laemmli Sample loading buffer. The 
mixture was boiled for 5 min at 98ºC followed by a brief centrifugation. Samples were 
then loaded onto a SDS-PAGE gel (5% stacking gel, 12% resolving gel), together with 
molecular weight markers (SeeBlue® Plus2 Pre-Stained Standard, Invitrogen). Running 
apparatus, voltage and time setting for gel running varied and depended on gel size. 
Transfer of proteins from the gels onto a membrane was achieved using a wet blotting 
procedure: gels were equilibrated briefly in transfer buffer followed by assembly of the 
transfer sandwich. This was organised in the following order: fiber pad, filter paper, pre-
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wetted membrane, equilibrated gel, filter paper, fiber pad. All were soaked in transfer 
buffer prior to use. A Hybond™ ECL™ (GE Healthcare) or Immobilon-FL (Millipore) 
membranes were used for ECL or immunofluorescence bas d membrane visualisation, 
respectively. Following completion of protein transfer the membrane was removed and 
washed briefly in dH2O.  
 
Two protein detection methods were used Enhanced Chemiluminescence (ECL) based 
detection or Near-infrared (NIR) fluorescence based d tection. This dictated different 
procedures for blocking, antibody incubation and signal detection which are detailed 
below. Antibodies usage and purchase details are provided in Tables 2.2- 2.4.  
 
2.5.3.1 Enhanced Chemiluminescence (ECL) based detection  
 
Membranes were incubated in blocking buffer (0.1% TBS-Tween, 5% skim milk 
powder (Sigma)), for 1 hr at room temperature or overnight in at 4°C. They were then 
washed 3 times, 5 min each, with TBS-Tween. Primary antibody diluted in TBS-Tween 
was added and membranes were incubated for 2 hr at room temperature or overnight at 
4°C. Excess antibody was washed as above. Secondary antibody diluted in blocking 
buffer was added and 2 hr incubation at room temperature was allowed. The membrane 
was then washed 3 times, 10 min each, with TBS-Tween. Finally, proteins were detected 
using the Amersham ECL™ Western Blotting Detection Reagents (Amersham, 
catalogue number RPN2109), X-ray film RX NIF (FujiFilm) and the OPTIMAX X-Ray 




2.5.3.2 Near-infrared (NIR) fluorescence based detection 
 
Membranes were incubated in PBS for several minutes followed by blocking with 
Odyssey blocking buffer (Li-Cor Biosceinces) diluted 1:1 in PBS, for 1 hr at room 
temperature. Primary antibodies diluted in Odyssey blocking buffer + 0.1% Tween-20 
were then added and a 2 hr at room temperature or overnight at 4°C incubation was 
allowed. Membranes were then washed 4 times, 5 min each, with 0.1% Tween PBS. All 
following steps were performed while protecting theantibody vials and membrane from 
light. Fluorescently-labelled secondary antibodies were diluted (typically 1:15,000) in 
Odyssey blocking buffer + 0.1% Tween-20 followed by a 60 min incubation at room 
temperature. The membranes were then washed 4 times, 5 min each, with 0.1% Tween 
PBS. Finally the membranes were rinsed with PBS and visualised using the Odyssey® 
Infrared Imaging System (Li-Cor Biosceinces). Images were analysed using the Odyssey 
Application Software version 3.0 (Li-Cor Biosciences): integrated fluorescence intensity 
was calculated for each protein band (defined as the sum of the intensity values for all 
pixels enclosed by a shape, i.e. a rectangle encompassing a single protein band, 
multiplied by the area of the shape (units are counts-mm2)). Quantification of the 
loading control protein (β- Actin or total p38) was used as a reference to normalize the 









# Catalogue number  
Antibody Host species Dilution  Incubation time Suplier  
Chroma 101; detects 
the  MCMV protein ie1 
Mouse 1:1000 Overnight, 4°C 
A kind gift from 




Chroma 103; detects 
the MCMV protein e1 
Mouse 1:1000 
2 hr, room 
temperature 
A kind gift from 




IkBalpha Rabbit 1:1000 
2 hr, room 
temperature 
Sigma (# I0505) 













anti-HA (clone 3F10) Rat 1:1000 
2 hr, room 
temperature 




Rabbit 1:500 Overnight, 4°C 
Santa Cruz 











Table 2.3: Secondary antibodies used for ECL based detection  
 
 
# Catalogue number  
 
 




# Catalogue number  
 
Antibody Dilution  Incubation time Supplier  
Peroxidase conjugated Affini Pure 
goat anti-mouse antibody IgG (H+L) 
1:3000 
2 hr, room 
temperature 
 Stratech (# 115035062) 
Peroxidase conjugated Affini Pure 
goat anti-rat antibody IgG (H+L)) 
1:3000 
2 hr, room 
temperature 
Stratech (# 115035062) 
Anti-rabbit IgG, HRP-linked 
Antibody 
1:2000 
2 hr, room 
temperature 
Cell Signaling 
Technology   (# 7074) 
Antibody Dilution  Incubation time Supplier  
 
Anti-mouse IgG (H+L) (DyLight 
800 Conjugate)  
1:15,000  
1 hr, room 
temperature 
Cell Signaling 
Technology   (# 5257) 
Anti-rabbit IgG (H+L) (DyLight® 
800 Conjugate)  
1:15,000 
1 hr, room 
temperature 
Cell Signaling 
Technology   (# 5151) 
Alexa Fluor® 680 goat anti-rabbit 
IgG (H+L) *highly cross-adsorbed* 
*2 mg⁄mL* 
1:15,000 
1 hr, room 
temperature 
Invitrogen                          
(# A-21109) 
Alexa Fluor® 680 goat anti-rat IgG 
(H+L) *2 mg⁄mL* 
 
1:15,000 
1 hr, room 
temperature 
Invitrogen                          
(# A-21096) 
Alexa Fluor® 680 goat anti-mouse 




1 hr, room 
temperature 




2.6 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Cytokine levels in cell culture supernatant were determined using ELISA kits in 
accordance with manufacturer’s instructions (R&D Systems Ltd, DuoSet ELISA 
Development Systems: Mouse TNFα catalogue number- DY410 and mouse IL-6 
catalogue number- DY406). In brief: a 96 well plate (96 well EIA/RIA Plate, Costar) 
was coated with capture antibody and incubated overnight at room temperature. On the 
following day wells were washed 3 times with wash buffer (0.05% Tween-20 in PBS). 
Samples or cytokine standard (100 µl) were then applied and incubated for 2 hr at room 
temperature. Plates were then washed as above and detection antibody added for an 
additional 2 hr incubation. Wells were again washed followed by addition of horseradish 
peroxidase (HRP) - conjugated streptavidin. After rmoval of non-bound HRP 
conjugate, the substrate solution was added and colour was allowed to develop for 20 
min. Colour development was then stopped by addition of 2 N H2SO4 solution. 
Absorbance was recorded using a POLARstar OPTIMA microplate Reader (BMG 
LabTech, UK). 
 
2.7 Immunofluorescence  
 
BMDM were seeded at a density of 1x105 cells/well onto BD Falcon CultureSlides (8 
chamber polystyrene vessel, BD Bioscience) and incubated overnight at 5% CO2 
atmosphere, 37°C. The next day cells were infected and treated as required then washed 
twice with PBS and fixed in 4% paraformaldehyde (PFA) for 15 min. Fixative was 
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removed by washing 3 times, 5 min each, with PBS and slides stored at 4°C until used. 
Preparation of cells for staining: cells were incubated with 50mM NH4CL in PBS for 
10min and washed twice, 5 min each, with PBS. Permeabilization was achieved by 
incubation with 0.5% Triton X-100 for 3 minutes followed by two washes with PBS. 
Immunostaining: cells were incubated in blocking buffer (PBS; 5% normal goat serum 
(Cell Signalling Technology, catalogue number 5425); 0.3% Triton X-100 (Sigma)) for 
1 hr. Primary antibodies diluted in antibody dilution buffer (1% BSA in PBS) were 
applied and overnight incubation at 4°C allowed. Cells were then washed 3 times, 5 min 
each, in PBS. This was followed by 2 hr incubation at room temperature with secondary 
antibodies also diluted in antibody dilution buffer. Excess antibody was removed by 
washing 3 times, 5 min each, with PBS. Finally slides were mounted using ProLong® 
Gold antifade reagent with DAPI (Invitrogen, catalogue number P-36931) and 
coverslips. The primary antibodies used were: NF-kB p65 (C22B4) (Cell Signaling 
Technology, catalogue number 4764) and Chroma 101 (see details in Table 2.2). The 
secondary antibodies used were: Alexa Fluor® 488 F(ab')2 fragment of goat anti-rabbit 
IgG (H+L) (Invitrogen, catalogue number catalogue number A-11070) and  Alexa 
Fluor® 594 F(ab')2 fragment of goat anti-mouse IgG (H+L) or Alexa Fluor® 488 Goat 
Anti-Mouse IgG (H+L) (Invitrogen, catalogue number catalogue number A-11001) and 
Alexa Fluor® 594 Goat Anti-Rabbit IgG (H+L) (Invitrogen, catalogue number catalogue 
number A-11012). Slides were analysed using the Leica SP5 confocal microscop with a 
x63 objective, numerical aperture 1.4. Microscope was operated and images acquired by 
Shonna Johnston, Optical Imaging Manager at the CALM - Confocal and Advanced 
Light Microscopy Facility, Queens’ Medical Research Institute, MRC Centre for 
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Inflammation Research, The University of Edinburgh. Images were prepared for print 
using ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011)   
 




ORF M45 was derived from a previously described clone collection of the MCMV 
orfeom (MCMV strain Smith) (Fossum et al., 2009). This clone library makes use of the 
Gateway® Technology system (Invitrogen) which is based on the recombination 
properties of bacteriophage lambda. It includes an array of plasmids containing different 
att sites which are DNA recombination sequences recognised by proteins that mediate a 
recombination reaction (Clonase™ enzyme mix).  This allows for a rapid and efficient 
transfer of genes of interest from an initial vector into which they were cloned 
(pDONR™ 207) into a variety of destination plasmids such as expression vectors. Two 
expression vectors were used: pCR3DEST and pCR3DESTHA. Both are derivatives of 
the pCR3 plasmid (Invitrogen) which have been previously adapted for use with the 
Gateway Technology system. The pCR3DESTHA plasmid includes an influenza virus 
hemagglutinin (HA) epitope tag at a N-terminal positi n. Transfer of M45 from 
pDONR™ 207 into pCR3DEST and pCR3DESTHA was achieved using an LR 
recombination reaction: 1 µl of pDONR™ 207, 1 µl of expression vector at a 
concentration of 300 ng/µl, 1 µl H2O, 1 µl LR clonase, quick spin, 2 hr incubation at 
room temperature. A schematic representation of an LR reaction and resulting plasmids 
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is shown in Figure 2.3. Following completion of the LR reaction transformation into 
chemically competent bacteria was performed. DNA from resulting colonies was 





Figure 2.3: Schematic representation of LR reaction . An LR reaction 
facilitates recombination of an attL substrate (entry clone = pDONR™ 207) with 
an attR substrate (destination vector = pCR3DEST or pCR3DESTHA) to create 
an attB-containing expression clone. This reaction is catalyzed by LR Clonase™ 
enzyme mix. For more information regarding the ccdB gene see section 2.9.2 
(adapted from the Gateway® Technology manual, Invitrogen). 
 
2.8.2 Purification of plasmid DNA  
 
For isolation of plasmid DNA, a single colony was selected from a LB plate and 
transferred to a 15 ml tube containing 3 ml of LB broth with the same antibiotic 
selection as the agar. The culture was incubated over night at 37°C with ~250 rpm 
shaking. The next day plasmid DNA was isolated using the QIAprep Spin mini prep kit 
(Qiagen). Alternatively, overnight culture was diluted 1:500 to inoculate 200 ml of 
growth media to be cultured overnight at 37°C with ~250 rpm shaking. This was used 
for preparation of larger DNA quantities using the Pureyield Plasmid Midiprep System 
(Promega). The concentration and purity of the purified DNA was determined by 
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measuring the UV absorbance at 260 and 280 nm (NanoDrop Spectrophotometer (ND-
1000), NanoDrop).  
 
2.8.3 Restriction endonuclease digestion 
 
Restriction enzymes EcoRV, HindIII, XbaI, corresponding buffers and BSA were 
purchased from New England BioLabs and used according to manufacturer’s 
recommendations. Typically a digestion mixture included: 5 µl of plasmid DNA isolated 
by mini-prep (see section 2.8.3), 20 U of each enzyme used, 1x enzyme appropriate 
buffer, 5 µg BSA, adjusted to a total volume of 30 µl with dH2O and incubated for 2 hr 
at 37°C.   
 
2.8.4 Agarose gel electrophoresis 
 
Agarose gels were used to analyze DNA fragments andplasmids. Gels (1% 
concentration) were made and run in 1xTAE buffer supplemented with ethidium 
bromide (final concentration 0.25 µg/ml).  A 1 kb DNA ladder (Generuler, Fermentas 








2.9 Bacterial methods 
 
2.9.1 Buffers and solutions for bacterial methods  
 
Luria-Bertani (LB) broth and agar plates:  10 g Tryptone (BD Biosceinces), 5 g Yeast 
extract (BD Biosceinces), 10 g NaCl (Sigma) and dH2O were mixed to a total volume of 
1 litre, autoclaved and kept at 4ºC. For plate prepa ation 15 g of agar (Sigma) was added 
and the mixture poured onto plastic plates (Sterilin limited, UK).  
 
Antibiotics:  Gentamycin (final concentration 15 µg/ml), Ampicillin (final concentration 
100 µg/ml), Chloramphenicol (final concentration 150 µg/ml) and Kanamycin (final 
concentration 50 µg/ml) were all purchased from Sigma.  
 
2.9.2 Bacteria  
 
Expression (destination) vectors used contain a ccdB gene which allows for negative 
selection of cells that have taken up unreacted destination and by-product vectors (see 
section 2.8.2 and Figure 2.3). This is due to the fact that the CccB protein inhibits the 
growth of most Escherichia Coli (E.coli) strains such as DH5α. Therefore, prior to 
insertion of the gene of interest these plasmids were propagated in the E. coli strain 
DB3.1 which is resistant to the CcdB effects. Following LR reaction (see section 2.8.2) 
plasmids were transformed into E.Coli strain DH5α to allow for negative selection. Both 
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strains were grown in LB medium or on LB agar plates at 37°C with constant shaking 
(~250 rpm) in the case of liquid media.  
 
2.9.3 Preparation of chemical competent bacteria  
 
A single colony of DH5α.bacteria was picked and grown over night in 10 ml of LB. The 
next day 5 ml of this starter culture was used to in culate 1 litre of LB. Inoculated 
culture was incubated at 37°C with shacking and bacterial growth assessed by measuring 
optical density at 600 nm OD600). Once an OD600 of ~0.5 was reached the exponential 
growth of the bacteria was stopped by swirling vigorously on ice for 10 min. The culture 
was then divided into two and centrifuged (4°C, 10 min at 4000 g-force) followed by re-
suspension in 30 ml of sterile, ice cold 100 mM CaCl2 per pellet.  This was followed by 
a 30 min incubation on ice and an additional centrifugation. Each pellet was gently re-
suspended in 5 ml ice cold sterile 100 mM CaCl2 supplemented with 15% glycerol 
(w/v). Resulting cells were aliquoted (50 µl), snap frozen in liquid nitrogen and stored at 
-80°C. 
 
2.9.4 Transformation of chemical competent bacteria  
 
Plasmid DNA (1 µl of LR reaction (see section 2.8.2)) was mixed with 50 µl chemical 
competent bacteria and sequential incubation steps w re conducted: 30 min on ice, 1.5 
min in 42°C water bath, 2 min on ice. Then LB media (800 µl) was added and the 
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mixture incubated for 1 hr, with shaking (950 rpm) on a hot block followed by spreading 
on appropriate selection plates.  
 
2.10 Statistical analysis  
 













3 Chapter 3 
 
MCMV inhibits IL-1 β induced I κBα degradation 
 
3.1 Introduction  
 
The cytokine IL-1β plays a key role in initiation and modulation of in lammation and 
additionally contributes to the shaping of adaptive immune responses (Sims and Smith, 
2010). IL-1β binding to its receptor leads to recruitment of MyD88 followed by IRAK1 
and IRAK4, TRAF6, TAK1 and finally the IKK complex. The IKK complex 
phosphorylates the NF-κB-inhibitor IκBα leading to its degradation and thus to 
activation of NF-κB (Weber et al., 2010). This MyD88 to NF-κB axis is also activated 
by TLRs (all except TLR3) (Kawai and Akira, 2010). Several TLRs, including TLR2, 
TLR7 and TLR9, have been shown to detect MCMV and contribute to host response 
against this pathogen (Tabeta et al., 2004) (Krug et al., 2004) (Zucchini et al., 2008) 
(Barbalat et al., 2009). Considering that MCMV is known to manipulate multiple other 
aspects of host anti-viral defence (Mocarski, 2002), it was hypothesised that MCMV 
specifically perturbs TLR- and IL-1β-induced signalling along the MyD88 to NF-κB 
pathway. To begin addressing this question this chapter aims to examine whether 
MCMV infection modulates the degradation of IκBα, the hallmark of NF-κB activation, 






3.2 Results  
 
3.2.1 System characterisation  
 
Fibroblasts are fully permissive to infection with MCMV, and constitutively express the 
IL-1β receptor. Therefore, MCMV infection of the fibroblast cell line NIH/3T3 followed 
by IL-1β treatment was chosen to evaluate the possible modulation of IL-1β signalling 
by this virus. Initially, basic characterisation of this system was carried out including 
preliminary examination of the effect of IL-1β on MCMV growth in NIH/3T3 cells and 
evaluation of IκBα degradation kinetics following cytokine stimulation in these cells.  
 
3.2.1.1 Effect of IL-1β on MCMV growth in NIH/3T3 cells 
 
To gain insight into the interplay between IL-1β and MCMV in the experimental system 
used, the effect of this cytokine on viral replicaton was examined. To this end a GFP 
expressing virus, MCMV-GFP (described in Chapter 2 section 2.3.1), was used. 
NIH/3T3 cells were treated with a range of concentrations of IL-1β prior to infection as 
well as maintained in cytokine containing media following infection. IFNβ treatment 
was used as positive control. Viral growth was monitored by microscopy (Figure 3.1a) 
as well as by measuring GFP signal (fluorescence intensity) over time (Figure 3.1b). As 
shown in Figure 3.1a, at day 2 post-infection only a small number of cells appear 
infected in non-treated cultures. This is followed by a rapid spread of infection with the 
majority of cells expressing GFP by day 4 post-infection. As expected, IFNβ treatment 
markedly reduced viral spread throughout the period examined. In IL-1β treated 
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cultures, at all time points evaluated, the number of infected cells appears equivalent or 
slightly higher than in non-treated cultures. Fluorescent signal measurements (Figure 1b) 
reflect these qualitative results. In comparison to non-treated cells, measured GFP 
expression is significantly lower in IFNβ treated wells. In contrast, no difference is 
observed following inclusion of IL-1β in the culture media up to 72 hr post-infection. At 
this time point a trend towards higher GFP intensity is seen in IL-1β treated wells in 
comparison to non-treated cultures. It is unclear if this is due to stronger GFP expression 









































Figure 3.1: Effect of IL-1 β on MCMV growth in NIH/3T3 cells . NIH/3T3 cells 
were treated with IL-1β at 0.1, 1 or 10 ng/ml or IFNβ at 50 U/ml for 8 hr followed 
by infection with MCMV-GFP (MOI = 0.02). Following infection cells were 
maintained in the presence of cytokines as per pre-infection treatment. (a) 
Whole well views of cell treated with IL-1β (10 ng/ml) or IFNβ (50 U/ml) were 
acquired at 2, 3 and 4 day post-infection. A representative experiment of three 
performed is shown (BF = Bright field; F = Fluorescence). (b) Viral replication 
was determined as a measure of GFP fluorescence. A representative 
experiment of three performed is shown. Each data point represents the 
average and standard deviation from six independent wells. 
 
* Image acquisition for section (a) of this figure was performed by Kimberly 





3.2.1.2 IκBα degradation kinetics following cytokine stimulation in NIH/3T3 cells 
 
The aim of this chapter is to examine whether MCMV infection modulates IL-1β-
induced IκBα degradation. To establish a temporal frame work fo measuring IL-1β-
induced IκBα degradation, the kinetics of this response were initially evaluated in non-
infected cells. As TNFα-induced IκBα degradation is known to be inhibited by MCMV 
(Le et al., 2008) (Mack et al., 2008), stimulation with this cytokine was included as a 
positive control throughout this chapter. Therefore, th  kinetics of TNFα-induced IκBα 
degradation were also evaluated. NIH/3T3 cells were treated with a range of IL-1β or 
TNFα concentrations. Whole cell lysates were collected at 15, 30 and 45 min following 
stimulation and analysed by Western blotting. Stimulation with IL-1β resulted in almost 
complete IκBα degradation by 15 min post stimulation. Thereafter, increasing IκBα 
amounts were observed with IκBα levels at 45 min post-treatment being comparable to 
pre-stimulation levels (Figure 3.2a). Treatment with TNFα resulted in almost identical 
degradation kinetics (Figure 3.2b). These results are in accordance with previously 
published kinetics of cytokine stimulated IκBα degradation in fibroblasts (Huang et al., 
2004) (Hoffmann et al., 2002). IκBα degradation kinetics were comparable between the 
different concentrations used, probably due to system saturation. Overall, at 15 min post 
IL-1β/ TNFα stimulation IκBα is largely degraded. The very low levels of IκBα at this 
time point provide an ideal background against which to measure any inhibition in IκBα 
degradation. It was therefore decided to use 15 min of cytokine treatment as the 
experimental time point in later experiments. 
 
 69
Figure 3.2: I κBα degradation kinetics following cytokine stimulatio n in 
NIH/3T3 cells . Cells were treated with different concentrations of TNFα (a) or 
IL-1β (b) for the indicated periods of time. Whole cell lysates were harvested 
and analysed using SDS-PAGE and immunoblotting with primary antibodies 






3.2.2 IκBα degradation following IL-1β stimulation is inhibited in MCMV-infected 
cells  
 
The aim of this chapter is to examine whether MCMV infection modulates the 
degradation of IκBα, the hallmark of NF-κB activation, following IL-1β stimulation. To 
begin examining this hypothesis, NIH/3T3 cells were mock treated or infected with 
MCMV, and at 7 hpi stimulated with IL-1β or TNFα. Whole cell lysates were prepared 
and analysed by Western blotting (Figure 3.3a). The time point used for cytokine 
stimulation, i.e. 7 hpi, was chosen for the following reasons: a) MCMV, as well as 
HCMV, attachment to the cell surface as well as infection initiate extensive cellular 
responses within minutes and hours (Yurochko et al., 1997) (Yurochko and Huang, 
1999) (Le et al., 2008) (Browne et al., 2001). It is of great interest to establish the 
interplay between the virus and these early cellular responses to infection. Early 
detection of infection is attributed at least in part to TLRs (Boehme et al., 2006). MCMV 
putative inhibition of TLRs as well as IL-1β signalling (the latter being the subject 
matter of this chapter) forms the central hypothesis for this thesis. It was therefore of 
interest to examine this hypothesis within early times post infection; b) this chapter 
focuses on IκBα levels as a measurement for signal transduction by IL-1β.  It has 
previously been shown that at 7 hpi IκBα levels in infected cells are comparable to those 
in mock-infected cells (Le et al., 2008). Indeed, in experiments presented here, prior to 
further stimulation, comparable IκBα levels were observed in mock- and MCMV-
infected cells. In accordance with published data (Le et al., 2008), while TNFα 
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stimulation of non-infected cells caused a drastic de rease in IκBα levels, MCMV 
infection inhibited the degradation of IκBα following treatment with this cytokine. 
Importantly, in infected cells treated with IL-1β levels of IκBα remained equivalent to 
those in infected but non-treated cells. To test whether this observation was due to 
inhibition of IκBα degradation or a kinetic change in the breakdown of this protein, 
mock and MCMV infected cells were treated with IL-1β for 15, 30 or 60 min (Figure 
3.3b). In non-infected cells cytokine stimulation resulted in almost complete degradation 
of IκBα at 15 min, followed by a slight recovery at 30 min a d a return to steady state 
levels at 60 min post treatment. In contrast, in MCMV-infected cells IκBα levels appear 
stable through out the time course with only a slight decrease observed at 15 min post 
treatment. These results indicate that IκBα degradation following IL-1β stimulation is 

















Figure 3.3: I κBα degradation following IL-1 β stimulation is inhibited in 
MCMV-infected cells . a) NIH/3T3 cells were mock infected or infected with 
MCMV (MOI = 5) and at 7 hpi stimulated with IL-1β (10 ng/ml) or TNFα 
(10 ng/ml) for 15 min. Whole cell lysates were harvested and analysed using 
SDS-PAGE and immunoblotting with primary antibodies against either IκBα or β-
Actin (n = 3). b) NIH/3T3 cells were mock infected or infected with MCMV 
(MOI = 5) and at 7hpi stimulated with IL-1β (10 ng/ml) for 15, 30 or 60 min. Cell 







3.2.3 De-novo viral gene expression is required for MCMV modulation of IκBα 
degradation following IL-1β stimulation  
 
In the previous section (3.2) it was demonstrated that in MCMV infected cells IL-1β 
stimulation does not result in a decrease in IκBα levels. To test whether this is dependent 
on de-novo viral gene expression, the MCMVdie3 mutant virus, which lacks the fifth 
exon of the ie1/ie3 transcription-unit, was used (for genomic map see Chapter 2). Gene 
expression of this mutant is limited to immediate-early genes ie1 and ie2, rendering the 
virus extremely growth deficient. Replication can be rescued by growing the virus on a 
complementary cell line (Bam25) expressing both IE1and IE3 (Angulo et al., 2000) 
(Lacaze et al., 2011). The most commonly used methods t  test the involvement of viral 
products in processes observed in infected cells are application of Cycloheximide (CHX) 
or infection with ultraviolet (UV)-inactivated virus. CHX blocks the translation of both 
cellular and viral proteins and thus would not have be n the method of choice for the 
work presented here, as it was preferable to isolate viral protein production without 
altering cellular protein synthesis. UV- inactivation damages viral DNA and thus renders 
the virus incapable of gene expression and DNA replication. The use of the MCMVdie3 
mutant virus in comparison to UV-inactivation offers the advantage of a phenotype 
reversal as MCMVdie3 mutant is able to grow on Bam25 cells. 
 
The growth characteristics of MCMVdie3 were re-evaluated in comparison to MCMV 
using PFU based single step (MOI = 2) growth curves. While infection of NIH/3T3 cells 
with MCMV resulted in productive infection, no viral growth for MCMVdie3 was 
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detectable in these cells (Figure 3.4a). Infection of Bam25 cells with the mutant virus 
resulted in recovery of viral replication although to somewhat attenuated levels in 
comparison to the wild type virus (Figure 3.4b). This is in agreement with previously 
published data and shows that MCMVdie3 is a viable virus if the IE3 protein is provided 
in trans.  Additionally, the kinetics of IκBα degradation in response to cytokine 
stimulation were tested in the Bam25 cell line.  Cells were treated with IL-1β or TNFα 
and following stimulation for 15, 30, 45 and 60 min whole cell lysates were collected to 
be analysed by Western blotting (Figure 3.5). IκBα degradation kinetics did not differ 
following stimulation with either cytokine. IκBα was quickly and drastically reduced (to 
10% of pre-stimulation levels) at 15 min post treatment. A slight recovery was recorded 
at 30 min (20% of pre-stimulation levels) with IκBα levels at 45 min post stimulation 
being comparable to those in non-treated. These results are similar to data obtained from 
NIH/3T3 cells. In both cell lines drastic degradation of IκBα was observed at 15 min 
post cytokine stimulation and recovery of protein levels observed thereafter. These 
results demonstrate that IκBα degradation in Bam25 cells is normal and additionally 
























Figure 3.4: Growth kinetics of MCMV and MCMVdie3 on  NIH/3T3 and 
Bam25 cells . NIH/3T3 (a) or Bam25 (b) cells were infected at MOI = 2 with 
MCMV or MCMVdie3. At indicated time points post infection (days post 
infection) supernatants from the infected cultures were harvested and titered on 
Bam25 monolayers. Error bars indicate the standard deviation from three 




















Figure 3.5: I κBα degradation kinetics following cytokine stimuli in  Bam25 
cells . Cells were treated with IL-1β (10 ng/ml) (a) or TNFα (10 ng/ml) (b) for the 
indicated periods of time. Whole cell lysates were harvested and analysed using 
SDS-PAGE and immunoblotting with primary antibodies against either IκBα or β-
Actin. Integrated fluorescence intensity was calculated (see Chapter 2 section 
2.5.3.2) for IκBα protein bands, normalised to corresponding β-Actin levels and 






Next, viral modulation of IL-1β induced IκBα degradation was compared in NIH/3T3 
cells infected with MCMV or MCMVdie3. To this end, cells were mock, MCMV or 
MCMVdie3 infected and at 7 hpi treated with either IL-1β or TNFα for 15 min. Whole 
cell lysates were prepared and analysed by Western blotting. As shown in Figure 3.3 an 
MOI of 5 was used for the initial experiment to ensure a maximum number of infected 
cells. However, in order to optimise the use of reagents, namely viral stocks, it was 
considered whether a lower MOI would produce comparable levels of infection in this 
cell culture system. NIH/3T3 fibroblasts are a fully permissive cell line commonly used 
in MCMV research (Ghazal et al., 2003). For a fully infection-permissive cell line such 
as NIH/3T3 fibroblasts it is possible to use a formula based on the Poisson distribution 
to calculate the fraction of the culture that is infected by a certain number of virus 
particles and also to estimate the total number of cells infected for a specific MOI (S. J. 
Flint, 2009). For example, it is estimated that ~ 95% and ~ 99% of cells will be infected 
when MOI of 3 and 5 are used, respectively (calculation was done by Muhamad Fairus 
.B.N. Hassim from The Division of Pathway Medicine, The University of Edinburgh, 
UK). Hence both a MOI of 3 and MOI of 5 would result in ≥ 95% of the culture 
infected. Therefore an MOI of 3 was considered sufficient for all subsequent 
experiments in this thesis. MCMVdie3 infection result  in ie1 expression, therefore, 
infection with both MCMV and MCMVdie3 could be confirmed by detection of IE1. 
Expression of IE1 was readily detectable in cells infected with wild type or mutant virus 
(indeed somewhat higher levels of IE1 were seen in MCMVdie3 infected cells than in 
MCMV infected cells) (Figure 3.6a + b). Stimulation f mock-infected cells resulted in a 
dramatic decrease in IκBα levels to ~10% of non-treated levels. This was inhibited to a 
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large degree in MCMV-infected cells in which post-stimulation IκBα levels were five 
times higher (~50%) of those in non-treated cells. The decrease in IκBα in MCMVdie3 
infected cells was the same as that observed in mock infected samples with a drop to 
~10% of pre-treatment IκBα levels. This was true for stimulation with IL-1β (Figure 
3.6a) as well as with TNFα (Figure 3.6b). These results indicate that immediat  early 
genes ie1 and ie2, which are expressed following infection with MCMVdie3, do not play 
a role in modulation of IκBα degradation following cytokine stimulation of infect d 
cells. Thus, in contrast to cells infected with MCMV, IL-1β stimulation of MCMVdie3 
infected cells does result in IκBα degradation.  
 
Finally, it was tested whether the MCMVdie3 virus is able to inhibit IL-1β signalling in 
the Bam25 cell line. To this end Bam25 cells were mock treated or infected with either 
MCMV or MCMVdie3 for 7 hr followed by stimulation with IL-1β or TNFα for 15 min. 
Whole cell lysates were collected and analysed by Western blotting. The results obtained 
from mock or MCMV infected cells were equivalent to those seen in NIH/3T3 cells 
(Figure 3.6). MCMVdie3 infection resulted in inhibition of IκBα degradation in a similar 
or even higher degree to that observed for infection with MCMV. IE1 was detected in 
both infected and non-infected cells as Bam25 cells stably express this protein (Figure 
3.7).  
Taken together these results indicate that IL-1β-induced IκBα degradation is inhibited in 




















Figure 3.6: MCMVdie3 does not inhibit I κBα degradation in IL-1 β 
stimulated NIH/3T3 cells . NIH/3T3 cells were mock infected or infected with 
MCMV or MCMVdie3 (MOI = 3). At 7 hpi cells were stimulated with IL-1β 
(10 ng/ml) (a) or TNFα (10 ng/ml) (b) for 15 min. Whole cell lysates were 
harvested and analysed using SDS-PAGE and immunoblotting with primary 
antibodies against IκBα, β-Actin or IE1. Integrated fluorescence intensity was 
calculated (see Chapter 2 section 2.5.3.2) for IκBα protein bands, normalised to 
corresponding β-Actin levels and expressed as percentage of IκBα in non-




















Figure 3.7: MCMVdie3 inhibits I κBα degradation in IL-1 β stimulated Bam25 
cells.  Bam25 cells were mock infected or infected with MCMV or MCMVdie3 
(MOI = 3). At 7 hpi cells were stimulated with IL-1β (10 ng/ml) (a) or TNFα 
(10 ng/ml) (b) for 15 min. Whole cell lysates were harvested and analysed using 
SDS-PAGE and immunoblotting with primary antibodies against IκBα, β-Actin or 
IE1. Integrated fluorescence intensity was calculated (see Chapter 2 section 
2.5.3.2) for IκBα protein bands, normalised to corresponding β-Actin levels and 






CMVs have co-evolved with their hosts and accordingly acquired multiple strategies for 
modulation of host immunity. Various TLRs including TLR2, TLR7 and TLR9 are now 
known to contribute to the initiation of host response to CMV infection (Tabeta et al., 
2004) (Krug et al., 2004) (Zucchini et al., 2008) (Barbalat et al., 2009). Signalling 
pathways activated by these TLRs as well as by the key pro-inflammatory cytokine 
IL-1β are characterised in great detail. However, little s known about the modulation of 
these signalling events during CMV infection. Work presented in this chapter examined 
whether IL-1β induced IκBα degradation is modulated in MCMV-infected cells.  
 
Initial characterisation of the interplay between IL-1β and MCMV included examination 
of the effect of this cytokine on viral replication i  3T3/NIH fibroblasts (Figure 3.1). 
IL-1β has been previously shown to inhibit the growth of HCMV in human foreskin 
fibroblasts (HFF) and marrow stromal cell lines (Iwata et al., 1999) (Randolph-Habecker 
et al., 2002). Additionally, pre-treatment of mouse embryonic fibroblasts (MEFs) with 
IL-1β was found to reduce MCMV virus titre at day 5 post infection in comparison to 
control cells (van der Meer et al., 1989). However, data presented here do not indicate 
IL-1β inhibition of MCMV replication. The disparity between these findings and 
previously published data could be due to the different cell types examined and/or 
cytokine treatment regimes used or the methods chosen to measure viral replication. It 
would be of interest to conduct further experiments utilising various cytokine-treatment 
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regimes and cell types as well to evaluate viral growth using plaque assay based growth 
curves.  
 
Data presented in this chapter show that in fibroblasts infected with MCMV the 
degradation of IκBα following IL-1β stimulation is inhibited in a manner dependent on 
de-novo viral gene expression (Figures 3.3, 3.6 and 3.7). It is noteworthy that the 
inhibition of IκBα degradation in infected cells was not complete i.e. a reduction in IκBα 
levels following cytokine stimulation was observed although markedly less than that 
seen in non-infected cells. In this regards the MOIs used and therefore the proportion of 
the culture expected to be and was actually infected should be considered. In the 
experiments shown (with the exception of Figure 3.3) an MOI of 3 was used which, as 
outlined above, is predicted to result in ~ 95% of cells being infected. Conversely, it is 
expected that a proportion of cells remain non-infected (~ 5% is predicted under optimal 
conditions but this percentage is presumably higher in culture and remains to be 
determined experimentally). In this cell population IL-1β stimulation will lead to IκBα 
degradation and this may account for at least a part of the observed reduction in IκBα 
levels following cytokine stimulation of infected cultures. The following approaches 
could be taken to further explore this possibility: - Determine the proportion of cells 
infected in the cell culture system used when different MOIs are applied (for example, 
by using the MCMV-GFP virus combined with flow cytometry analysis to establish the 
percentage of infected cells); - Compare IL-1β- induced IκBα degradation between 
cultures infected with various MOIs (for example, MOI of 1, 3 and 5). Importantly, 
IL-1β can induce IκBα dissociation from NF-κB and thus NF-κB activation in a manner 
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independent of IκBα degradation (Yao et al., 2007) (Yamazaki et al., 2009). Therefore, 
further experiments are needed to establish how observations presented here correlate 
with NF-κB nuclear translocation, DNA binding and importantly functional outcomes 
such as expression of NF-κB inducible genes.  Finally, these data do not distinguish 
between specific inhibition of IL-1β signal transduction at a step upstream of NF-κB and 
its immediate regulatory network or a general block n NF-κB activation imposed by the 
virus or a combination of the two. Interestingly, Le et al showed that MCMV extends 
the stability of IκBα, under CHX treatment, beginning at approximately 5 hpi (Le et al., 
2008). The significance of this observation, how it may correlate with the data presented 
here and whether it indicates viral modulation of the function of IκBα and therefore of 
NF-κB remains to be seen.  
 
HCMV has previously been shown to suppress IL-1β as well as TNFα induction of 
cytokine and chemokines expression (Jarvis et al., 2006) (Montag et al., 2006). 
Interestingly, this was found to be distinctly regulated. In HCMV infected cells IL-1β 
failed to induce IκBα phosphorylation and degradation as well as NF-κB nuclear 
translocation. In contrast, IκBα processing following TNFα stimulation did take place 
albeit with retarded kinetics. As IL-1β and TNFα signal through distinct pathways 
converging on the IKK complex, it was concluded that HCMV alters signal transduction 
by these cytokines upstream of IKK activation in a pathway specific manner. However, 
the viral proteins mediating this effect or the underlying mechanism were not defined  
(Jarvis et al., 2006). In the work presented here viral inhibition of TNFα signalling was 
used as a positive control since MCMV has been shown t  modulate this pathway prior 
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to IKK activation via disruption of RIP1 function (Mack et al., 2008). As RIP1 is not 
known to function in the context of the IL-1β signalling pathway it is unlikely that this 
mechanism explains the observation made here. However, this does not exclude the 
existence of additional viral mechanisms altering both TNFα and IL-1β signalling. 
Finally, both HCMV and MCMV have previously been shown to down regulate the 
expression of TNFR1 (Montag et al., 2006) (Popkin and Virgin, 2003). It remains to be 
tested whether expression of the IL-1β receptor is modulated by MCMV infection.  
 
Overall, a previously unknown MCMV modulation of IκBα degradation following IL-1β 
stimulation is shown in this chapter, establishing a  experimental framework in which to 
further test the hypothesis of this thesis. 
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4 Chapter 4 
 





The MCMV protein M45 inhibits PRR and pro-inflammatory cytokine signalling as well 
as serving as a key suppressor of both intrinsic and extrinsic cell death mechanisms 
(Brune et al., 2001) (Mack et al., 2008) (Upton et al., 2010). Mutation of this gene 
renders MCMV effectively avirulent in SCID mice including failure to replicate in target 
organs (Lembo et al., 2004). To date, M45 functions in modulation of cellular responses 
have been attributed to its binding of receptor interacting protein (RIP) family members, 
namely RIP1 and RIP3 (Mack et al., 2008) (Upton et al., 2010). RIP proteins are 
serine/threonine kinases activated in response to cellular stress signals such as PRR 
activation, death receptor ligation and DNA damage. Activation of RIP proteins results 
in stimulation of cellular transcription factors such as NF-κB and MAPKs as well as in 
induction of cell death (Festjens et al., 2007) (Declercq et al., 2009) (Meylan and 
Tschopp, 2005). M45 was initially described as a cell tropism determinant, required for 
inhibition of cell death in endothelial cells (Brune et al., 2001). Further studies 
demonstrated that M45 inhibits infection-induced RIP3-dependent necrosis and is 
therefore required for viral growth in RIP3 expressing cells (Upton et al., 2010). In 
addition, M45 abrogates TNFα-induced programmed necrosis, also termed necroptosis, 
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a process dependent on both RIP1 and RIP3 (Mack et al., 2008) (Upton et al., 2010). 
Upton et al mapped the RIP1/3 interaction domain on M45 to a RIP homotypic 
interaction motif (RHIM) domain, present in all three proteins (RIP1, RIP3 and M45) 
(Upton et al., 2008). A mutant virus M45mutRHIM, carrying alanine substitutions 
disrupting the RHIM domain, was found incapable of inhibiting virus-induced RIP3-
dependent cell necrosis as well as necroptosis. Importantly, the attenuated in-vivo 
phenotype of M45mutRHIM (as measured by lack of footpad swelling and iab lity to 
recover replicating virus from salivary-glands) is reversed in RIP3 knock-out animals, 
thus demonstrating that RHIM-dependent M45 interactions specifically target RIP3 
function (Upton et al., 2010). In addition to the above mentioned inhibition of TNFα 
mediated necroptosis, M45 also disrupts NF-κB and p38 activation by this cytokine 
(Mack et al., 2008). This M45 function was attributed to M45 binding to RIP1, which is 
necessary for TNFα signal transduction (Mack et al., 2008) (Kelliher et al., 1998) (Lee et 
al., 2003). In contrast to the finding by Upton et al described above, Mack et al found 
M45 binding with RIP1 to be independent of RHIM interactions (Mack et al., 2008). 
Finally, M45 inhibits TLR3 and DAI induced NF-κB activation, presumably via 
interaction with RIP1 and RIP3 (Mack et al., 2008) (Rebsamen et al., 2009). RIP1 
participates in the TLR3 signalling pathway following recruitment to the TRIF, itself a 
RHIM domain containing protein (Cusson-Hermance et al., 2005). Two RHIM domains 
are present in DAI and serve to bind both RIP1 and RIP3 (Kaiser et al., 2008). The 




In the previous chapter, MCMV infection was shown to modulate the degradation of 
IκBα following stimulation with IL-1β. Experiments were performed at 7 hpi, a time 
point at which M45 is expressed in infected cells (albeit to lower levels than at later 
times post infection) (Lacaze et al., 2011) (Upton et al., 2010). M45 has been shown to 
inhibit NF-κB activation by TNFα and other PRRs all of which utilise RIP1 as an 
obligatory signalling module. While RIP proteins don t play a role in IL-1β signalling 
(Weber et al., 2010) (Meylan et al., 2004), they are, interestingly, related to IRAK 
family members, which perform a key role in the IL-1β pathway (Meylan and Tschopp, 
2005) (Manning et al., 2002). The aim of this chapter is to examine whether M45 plays a 




4.2 Results  
 
4.2.1 M45 inhibits IL-1β induced IκBα degradation  
 
To test whether M45 plays a role in MCMV inhibition of IL-1β-induced IκBα 
degradation, NIH/3T3 cells were mock treated or infected with MCMV, a M45 deletion 
mutant (∆M45) or complement virus into which M45 has been re-introduced (CM45). 
Mock treated and infected cells were stimulated with IL-1β, at 7 hpi, for 15 min. Whole 
cell lysates were prepared and analysed by Western blotting (Figure 4.1a). Expression of 
IE1 was equivalent following infection with all three viruses. IκBα levels prior to IL-1β 
stimulation were comparable between non-infected cells and cells infected with any of 
the three viruses. This is in agreement with previously published data (Mack et al., 
2008). IκBα levels decreased dramatically following IL-1β treatment of mock infected 
cells but remained stable in MCMV or CM45 infected cells. In ∆M45-infected cells, the 
fall in IκBα levels was equivalent to that in non-infected cells. Thus, M45 is necessary 
for inhibition of IκBα degradation following IL-1β stimulation of MCMV infected cells. 
It was then asked whether M45 is sufficient to block IL-1β-induced IκBα degradation. 
Cells were transfected with M45 or HA-M45 expression vectors followed by stimulation 
with IL-1β. Whole cell lysates were prepared and analysed by Western blotting (Figure 
4.1b). IL-1β stimulation of cells transfected with empty or a GFP expression vector 
resulted in almost complete degradation of IκBα. However, in cells transfected with 
vectors expressing M45 or tagged M45, IκBα degradation was markedly inhibited. The 
partial decrease in IκBα levels observed in M45 or tagged M45 transfected clls may 
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represent non-transfected cells. Taken together, thse results show that M45 is necessary 























Figure 4.1: M45 inhibits IL-1 β induced I κBα degradation. a) NIH/3T3 cells 
were mock treated or infected with MCMV, ∆M45 or CM45 (MOI = 3). At 7 hpi 
cells were stimulated with IL-1β (10 ng/ml) for 15 min. Whole cell lysates were 
harvested and analysed by using SDS-PAGE and immunoblotting with primary 
antibodies against IκBα, β-Actin or IE1. Data shown are representative of at 
least three independent experiments. Integrated fluorescence intensity was 
calculated (see Chapter 2 section 2.5.3.2) for IκBα protein bands, normalised to 
corresponding β-Actin levels and expressed as percentage of IκBα in non-
stimulated cultures (n = 3). b) NIH/3T3 cells were mock treated (M), or 
transfected with empty vector (V), GFP, M45 or HA-M45 expression vectors. At 
12 hr post transfection cells were treated with IL-1β (10 ng/ml) for 15 min. Whole 
cell lysates were harvested and analysed by using SDS-PAGE and 




4.2.2 p38 phosphorylation in MCMV infected cells following IL-1β stimulation 
 
IL-1β activates MAPKs cascades as well as NF-κB (Weber et al., 2010). IL-1β 
stimulation leads to activation of TAK1, a MAPK kinase kinase, which in addition to its 
interaction with the IKK- NF-κB system also activates MAPK kinases. In turn, MAPK 
kinases, namely MEK3/MEK6 and MEK4/MEK7, phosphorylate and thus activate p38 
and JNK family members, respectively. In view of the observation that M45 inhibits 
IL-1β-induced IκBα degradation, it was asked whether M45 also modulates the 
phosphorylation of p38 to p-p38.  
The kinetics of p38 phosphorylation in response to IL-1β stimulation of NIH/3T3 cells 
were initially examined. Whole cell lysates were collected at 0, 4, 8, 12, 16 and 20 min 
following IL-1β treatment and analysed by Western blotting. Phosphorylation of p38 
increased significantly within 4 min of stimulation and continued to rise at 8 min of 









Figure 4. 2: p38 phosphorylation kinetics following IL-1β stimulation  in 
NIH/3T3 cells. NIH/3T3 cells were treated with IL-1β (10 ng/ml) for the indicated 
periods of time. Whole cell lysates were harvested and analysed using SDS-
PAGE and immunoblotting with primary antibodies against either p-38 or p-p38 
(n = 2). 
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Next, p38 phosphorylation following IL-1β stimulation was tested in MCMV infected 
cells. NIH/3T3 cells were mock treated or infected with MCMV, ∆M45 or CM45 and at 
7 hpi treated with IL-1β for 0, 4, 8, 12 and 16 min. Whole cell lysates were p epared and 
analysed by Western blotting (Figure 4.3a and 4.3b). p38 phosphorylation followed a 
similar pattern in mock treated cells or cells infected with either wild-type or mutant 
viruses: levels of p-p38 quickly rose in response to IL-1β, peak phosphorylation was 
observed at 8 to 12 min post-stimulation with comparable fold change increase observed 
for all conditions (mock infection or infection with the different viruses), followed by a 
drop in p-p38 levels. It should be noted that the kinetics of phosphorylation and 
dephosphorylation did differ between experiments. Importantly, however, within each 
experiment the rate of p38 phosphorylation/dephosphrylation was similar under all 
conditions (mock infection or infection with the different viruses) ( with exception of 
∆M45-infected cells in Figure 4.3a in which dephosphorylation of p-p38 appears to be 
of slower kinetics than in mock-, wild-type- or CM45- infected cells). Finally, p38 
phosphorylation following IL-1β stimulation was compared in cells productively or n n-
productively infected with MCMV. NIH/3T3 cells were mock treated or infected with 
MCMV or MCMVdie3 and at 7 hpi treated with IL-1β for 0, 4, 8, 12 and 16 min. Whole 
cell lysates were prepared and analysed by Western blotting (Figure 4.3c). IL-1β 
induced p-38 phosphorylation kinetics were highly similar in mock, MCMV or 
MCMVdie3 infected cells: levels of p-p38 quickly rose in response to IL-1β, peak 
phosphorylation (~ 3 fold increase in comparison to m ck non-stimulated cells) was 
observed at 8 min post-stimulation, followed by a drop in p-p38 levels. Finally, results 
obtained for mock and MCMV infected cells in the three independent experiments 
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shown in Figure 4.3a-c were statistically analysed (Figure 4.3d). It was found that IL-1β 
induced p-38 phosphorylation kinetics does not differ, at least at the time post infection 
examined, in MCMV infected cells in comparison to non-infected cells. Taken together, 
these results indicate that MCMV, and specifically M45, do not inhibit the 
























































Figure 4.3: p38 phosphorylation in MCMV infected ce lls following IL-1 β 
stimulation.  a) and b) NIH/3T3 cells were mock infected or infected with 
MCMV, ∆M45 or CM45 (MOI = 3). At 7 hpi cells were stimulated with IL-1β 
(10 ng/ml) for indicated periods of time. Whole cell lysates were harvested and 
analysed by using SDS-PAGE and immunoblotting with primary antibodies 
against p38 and p-p38. Integrated fluorescence intensity was calculated (see 
Chapter 2 section 2.5.3.2) for p-p38 protein bands, normalised to corresponding 
p38 levels and expressed as fold change as compared with non-infected cells at 
min 0. Calculated fold change in p-p38 levels is shown below gel images and 
plotted in accompanying graphs (n = 2). c) NIH/3T3 cells were mock infected or 
infected with MCMV or MCMVdie3 (MOI = 3). At 7hpi cells were stimulated with 
IL-1β (10 ng/ml) for indicated periods of time. Whole cell lysates were harvested 
and analysed as described above (n = 1). d) Graph showing average fold 
change in p-p38 levels calculated for IL-1β- treated mock and MCMV infected 
cells in the three independent experiments shown in a – c  (error bars indicate 






In the previous chapter IL-1β-induced IκBα degradation was found to be modulated in 
MCMV infected cells. Data presented in the current chapter demonstrates that MCMV 
protein M45 mediates this effect.   
 
M45 is shown here to inhibit IL-1β-induced IκBα degradation (Figure 4.1). M45 has 
previously been shown to inhibit both innate-immune receptor signalling (namely TNFα, 
TLR3, DAI) as well as cell death induced by infection. These M45 functions were 
attributed to its ability to bind and modulate the function of cellular-stress signal 
transducers RIP1 and RIP3 (Mack et al., 2008) (Upton et al., 2010). RIP proteins are not 
known to take part in the IL-1β pathway (Weber et al., 2010) (Meylan et al., 2004).  
Therefore, M45 inhibition of signalling events described here likely represents a novel 
function of this protein. Further experiments are required to substantiate this conclusion 
by establishing the underlying protein-protein interactions and mechanism.  
 
M45 does not appear to inhibit p38 phosphorylation in response to IL-1β (Figure 4.3). 
IL-1β binding to its receptor induces, via IRAKs and TRAF6, the activation of TAK1. 
At this point the signalling pathway bifurcates as TAK1 activates the IKK complex 
followed by NF-κB, as well as phosphorylates MAPK kinases resulting in p38 and JNKs 
phosphorylation/activation. It was therefore of interest to establish whether M45 
perturbs only one or both arms of the pathway. Interestingly, IL-1β-induced p38 
phosphorylation was not found to differ between non-infected and MCMV-infected cells 
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regardless of viral gene expression including M45 (Figure 4.3). It should be noted that 
p38 phosphorylation kinetics differed somewhat betwe n the experiments conducted. 
Importantly, however, within each experiment the rate of p38 
phosphorylation/dephosphorylation was similar under all conditions (mock infection or 
infection with the different viruses). Differences observed could be resolved with further 
repetition of experiments shown as well as by using more sensitive techniques such as 
ELISA. In this regards the MOIs used and therefore th  proportion of the culture 
expected to be infected should also be considered. In the experiments presented here a 
MOI of 3 was used which is predicted to result in the grand majority of cells being 
infected. Conversely, it is expected that a small proportion of cells remain non-infected 
(this question of the ratio between these populations f infected and non-infected cells is 
discussed in more detail in Chapter 3). In the non-i fected cell population IL-1β 
stimulation will lead to p38 phosphorylation and thus contribute to the proportion of 
p-p38 observed following cytokine stimulation of infected cultures. It would be of 
interest to compare the levels of IL-1β  induced p38 phosphorylation between cultures 
infected with various MOIs (for example, MOI of 1, 3 and 5). This said, NIH/3T3 is a 
fully infection-permissive cell line and a MOI of 3is expected to result in the 
predominant portion of cells being infected. Therefo , it is safe to conclude that the 
IL-1β- induced increase in p-p38 observed in infected cultures does indeed represent p38 
phosphorylation occurring in infected cells.  
 
p38 activation, following IL-1β stimulation, is considered entirely dependent on TAK1 
(Sato et al., 2005) (Weber et al., 2010). Thus, the finding that p38 is phosphorylated 
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suggests, that in the experimental settings used, TAK1 is activated. This in turn may 
indicate that the observed inhibition of IκBα degradation is a result of M45 interference 
with a signalling step between TAK1 activation and IκBα degradation. Possible points 
of viral interference include: inhibition of TAK1 phosphorylation of the IKK complex, 
modulation of the IKK complex itself (for example the abundance of IKKα, IKKβ or 
IKK γ) or its activity (for example blockage of kinase functions) or interference with 
IκBα processing for degradation (at or after its ubiquit nation). In other words, these 
results may indicate that M45 modulates the functio of the immediate regulatory circuit 
of NF-κB.  
 
It is also possible that the activation of NF-κB and p38 is differentially modulated by the 
virus. Activated p38, through phosphorylation of multiple and diverse substrates, 
regulates various cellular processes including protein degradation and localization, 
mRNA stability, endocytosis, apoptosis and cytoskeleton dynamics (Cargnello and 
Roux, 2011) (Cuadrado and Nebreda, 2010). The overall outcome of p38 driven 
processes or that of a subset of them might contribute to a formation of a favourable 
cellular environment for viral replication. This in turn may have selected for either virus 
non-interference with or even potentiation of p38 activ tion. An interesting example is 
that of vaccinia virus protein A52R. In transfection experiments this protein inhibits 
NF-κB activation by multiple TLRs via interaction with IRAK2, presumably disrupting 
the ability of IRAK2 to engage its cellular interaction partners (Keating et al., 2007) 
(Harte et al., 2003) (Bowie et al., 2000). At the same time, by binding to TRAF6, A52R 
potentiates the activation of p38 and JNK upon TLR stimulation. It has been 
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hypothesised that by A52R can selectively induce downstream signalling by TRAF6 
(that is, A52R may induce p38 phosphorylation without affecting NF-κB activation) 
(Maloney et al., 2005). This differential effect reflected in A52R modulation of LPS-
induced gene expression such that NF-κB-dependent expression of IL-8 was inhibited 
while p-38 dependent expression of IL-10 was enhanced (Maloney et al., 2005). In the 
case of MCMV and M45, it is noteworthy that M45 does inhibit TNFα-induced p38 
phosphorylation (Mack et al., 2008). M45 modulation of TNFα signalling is thought to 
be due to M45 binding to RIP1 (Mack et al., 2008). RIP1 is a regulator of several 
cellular stress responses including those originating from activation of PRRs and by 
death receptor ligation and DNA damage (Meylan and Tschopp, 2005). Hence M45 
modulation of RIP1 function can be considered as viral interference with a hub of 
cellular signalling. Inhibition of TNFα-induced RIP1-dependent p38 activation can 
therefore be viewed as an inevitable consequence of M45 targeting RIP1 rather than a 
result of M45 primarily targeting p38.  
 
The inter-relationship between HCMV/MCMV and NF-κB has been previously studied 
in some detail. Infection with either HCMV or MCMV induces NF-κB activation. 
HCMV infection results in rapid translocation of NF-κB to the nucleus, stimulation of 
NF-κB DNA binding activity and transcription initiation (Kowalik et al., 1993) 
(Yurochko et al., 1997) (Yurochko and Huang, 1999). Indeed, viral envelope 
glycoproteins gH and gB alone have been shown to elicit the activation of NF-κB, 
potentially through detection by TLR2 (Yurochko et al., 1997) (Yurochko and Huang, 
1999) (Boehme et al., 2006). Similarly, MCMV infection induces IκBα degradation, NF-
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κB DNA-binding activity and associated transcriptional regulation (Gribaudo et al., 
1996) (Le et al., 2008). NF-κB activation following infection is attributed, at least 
partially, to stimulation by PRRs including TLR induced NF-κB activation (Tabeta et 
al., 2004) (Zucchini et al., 2008) (Krug et al., 2004).  
 
It has been previously suggested that one way CMVs may have adapted to the activation 
of NF-κB is by harnessing its transcriptional activity to augment viral gene expression 
and replication (Sambucetti et al., 1989). In both HCMV and MCMV the enhancer of 
the major immediate-early enhancer promoter (MIEP), which regulates immediate-early 
gene expression, contains binding sites for cellular tr nscription factors including 
NF-κB, AP1 and CREB/ATF (Stinski and Isomura, 2008). Additionally, NF-κB 
complexes have been shown to bind to HCMV enhancer derived sequences and up-
regulate the expression of reporter genes (Sambucetti et al., 1989) (Prosch et al., 1995). 
It was therefore hypothesised that NF-κB activation is required for the initiation of viral 
immediate-early gene transcription and therefore vial replication. However, disruption 
of the NF-κB binding sites with the HCMV enhancer does not alter IE1 expression or 
viral growth kinetics in cultured cells (Gustems et al., 2006). These data are supported 
by in vivo investigations. An intact HCMV enhancer or an enhancer in which the NF-κB 
binding sites were silenced were used to replace the MCMV enhancer, resulting viruses 
were named hMCMV-ES and hMCMV-ES.NF-κB, respectively (an enhancer swap 
approach was used due to prohibitive to manipulation properties of the MCMV enhancer 
on one hand and the need for in-vivo investigation on the other hand). In an in-vivo 
model of neonatal infection no difference was found between the growth of the 
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hMCMV-ES and hMCMV-ES.NF-κB viruses (Isern et al., 2011). Importantly, in the 
same model system an enhancer swap virus in which bot  NF-κB and AP1 enhancer 
binding sites were mutated showed significant attenuated growth (Isern et al., 2011). In 
addition, serum response factor (SRF) and est-like gene-1 (Elk-1) binding sites have 
been shown to compensate for NF-κB mediated activation of MIEP (Caposio et al., 
2010). This suggests that enhancer usage of various cellular transcription factors allows 
for robustness such that elimination of input by one transcription factor is compensated 
by others (Caposio et al., 2010) (Isern et al., 2011). This is turn implies that the role of 
NF-κB in activation of immediate-early viral gene transcription can only be understood 
in the context of a complex fine-tuned “conversation” between the CMV-MIEP 
enhancer and the transcriptional response to infecton (Stinski and Isomura, 2008). 
Finally, impairment of the canonical NF-κB pathway, using an IκBα dominant negative 
mutant, a IKKβ dominant negative mutant or p65 knock-out cells, did not affect HCMV 
or MCMV replication in-vitro (Benedict et al., 2004) (Caposio et al., 2007). Indeed, at 
low MOI (0.02) replication of MCMV on p65-deficient fibroblasts was enhanced 
(Benedict et al., 2004). Interestingly, expression of an IKKβ dominant negative mutant 
did block HCMV replication in quiescent cells (Caposio et al., 2007). Overall, in 
cultured cells NF-κB activation appears to have a neutral, if not inhibitory, role in CMV 
replication although additional work is required to assess its contribution to the viral life 
cycle in quiescent cells and in-vivo relevant cell types such as endothelial and primary 




HCMV, in addition to the above discussed activation of NF-κB, has been shown to 
disrupt NF-κB activation and function. Taylor et al have demonstrated that IE86, the 
HCMV immediate-early 2 gene product, blocks NF-κB binding to DNA (although it 
does not affect IκBα degradation or NF-κB nuclear translocation). This results in 
inhibition of infection-induced expression of IFNβ as well as inflammatory genes 
(TRAIL, IL-6). TNFα-induced NF-κB DNA binding and upregulation of inflammatory 
genes (IL-8 and RANTES) expression is also inhibited by IE86. Interestingly, IE86 was 
not found to bind to NF-κB subunits p50 or p65. It was hypothesised by the authors that 
modulation of NF-κB function by IE86 is achieved by binding to a NF-κB interaction 
partner or by modulation of pathways controlling the post-transcriptional modification 
of p65 (Taylor and Bresnahan, 2006). In addition, NF-κB activation following 
stimulation with IL-1β or TNFα is inhibited in HCMV infected cells (Montag et al., 
2006) (Jarvis et al., 2006). This inhibition occurs pstream of IL-1β and TNFα signalling 
pathways convergence on NF-κB and appears to be pathway specific rather than a result 
of viral modulation of NF-κB function (Montag et al., 2006) (Jarvis et al., 2006).    
 
MCMV has also been shown modulate NF-κB activation. As discussed above, MCMV 
protein M45 inhibits several signalling pathways leading to NF-κB activation by binding 
to cellular proteins RIP1 and RIP3 (Mack et al., 2008) (Upton et al., 2008). Examination 
of NF-κB activation kinetics following MCMV infection showed that IκBα degradation 
and NF-κB DNA-binding activity were induced following infection, however, both were 
dampened by 6 hpi (i.e. by this time point both cytoplasmic IκBα and nuclear NF-κB-
DNA complexes returned to pre-infection levels) (Le et al., 2008). Additionally, 
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stimulation of infected cells with TNFα at 7 hpi did not result in IκBα degradation. 
Interestingly, under cycloheximide treatment IκBα intrinsic half-life increased 
significantly in infected cells versus controls (Le et al., 2008). The authors concluded 
that these finding indicate that NF-κB activation is controlled by MCMV. However, the 
underlying mechanism or viral product/s mediating this effect were not elucidated (Le et 
al., 2008). Considering that M45 is expressed at 6 hpi (Lacaze et al., 2011) (Upton et al., 
2010) and the above suggested hypothesis that M45 modulates NF-κB activation, it   
would be of interest to examine infection-induced NF-κB activation (nuclear 
translocation, DNA binding and transcriptional activation of target genes) over time in 
cells infected with wild type versus UV-inactivated virus and the M45 deletion mutant.  
 
Overall, data presented here identifies M45 as the MCMV protein mediating viral 
inhibition of IL-1β induced IκBα degradation. Additionally, preliminary observations 
suggest that M45 directly modulates the immediate NF-κB regulatory circuit. Although 
the interaction between HCMV/MCMV infection and NF-κB activation has been 
researched in some detail there is much to learn. Indeed, much of the research described 
in the literature (as briefly reviewed above) explored the overall effect of NF-κB 
activation or lack thereof on CMV replication. Alternatively, NF-κB activation was used 
as marker in investigations into viral modulation of signalling by cytokines or PRRs. 
However, little is known about direct CMV targeting of NF-κB as a major cellular 
signalling hub synthesising signals from multiple pathways (this is with the exception of 
the study by Taylor et al). In the case of MCMV, previous studies alluded to the fact that 
NF-κB activation might be controlled by the virus. However, the underlying mechanism 
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or viral product/s mediating this effect were not elucidated (Le et al., 2008). Thus the 
findings presented here, which identify M45 as a potential direct modulator of NF-κB 
function, can form the basis for detailed investigations into MCMV- NF-κB interplay. 
Thus, allowing research in this field to progress from observational to mechanistic 
studies which put this key signalling factor, namely NF-κB, at the heart of the research 
effort. This may include more detailed mapping of temporal regulation during infection 
and the resulting differential effects on gene exprssion, detailed understating of M45 
interaction with the NF-κB network and identification of additional viral products 




5 Chapter 5  
 
MCMV modulates NF- κB activation following TLR7 or TLR9 
stimulation in bone marrow-derived macrophages 
 
5.1 Introduction  
 
TLR7 and TLR9 are intracellular TLRs capable of detecting nucleic acids (Blasius and 
Beutler, 2010). TLR9 is often quoted as recognising hypo/unmethylated CpG-rich DNA 
that is more frequently present in the genomes of microbes than in mammalian DNA 
(Blasius and Beutler, 2010). However, several studies have now demonstrated that DNA 
recognition by TLR9 is dependent on the 2’-deoxyribosephosphate backbone. 
Furthermore, these studies suggest that chemical modifications and specific sequences 
present in synthetic CpG-oligodeoxynucleotides (ODNs)  ligands used in TLR9 research 
actually serve to improve delivery into intracellular compartments of TLR9 expression 
rather than facilitating the ligand-TLR9 interaction itself (Haas et al., 2008) (Yasuda et 
al., 2005) (Yasuda et al., 2006). TLR7 detects ssRNA as well as the low molecular 
weight synthetic compounds called imidazoquinolines, for example resiquimod (R-848), 
and guanine analogs (Hemmi et al., 2002) (Diebold et al., 2004) (Heil et al., 2004) (Lund 
et al., 2004). Both TLR7 and TLR9 localize to an endosomal compartment and are 
activated only in acidified endolysosomal compartments (Blasius and Beutler, 2010). It 
is thought that this particular localization/activaon profile is important in 
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discrimination between self and non-self nucleic acids as host DNA is usually excluded 
from these intracellular bodies (Barton and Kagan, 2009) (Blasius and Beutler, 2010).    
 
TLR7 and TLR9 induced responses are cell-type dependent. In conventional dendritic 
cells (cDCs) and macrophages stimulation of these TLRs leads to MyD88-dependent 
activation of NF-κB and MAPK pathways resulting in secretion of inflammatory 
cytokines. This occurs via the IRAKs-TRAF6-TAK1 signalling cascade. NF-κB 
activation is enabled via TAK1 activation of the IKK complex followed by 
phosphorylation and degradation of NF-κB inhibitor IκBα (reviewed in Chapter 1). In 
plasmacytoid dendritic cells (pDCs) activation of TLR7 and TLR9 leads, in addition to 
NF-κB and MAPKs activation, to secretion of type I IFN (Blasius and Beutler, 2010).  
 
As reviewed in Chapter 1, both TLR9 and TLR7 have be n shown to play a role in host 
response to MCMV. MCMV infection of TLR9 knock-out (TLR9-/-) mice or mice with 
a non-functional TLR9 receptor results in increased mortality and elevated viral titres in 
the spleen in comparison to wild type animals. This correlates with impaired cytokine 
responses and diminished activation of NK cells (Delale et al., 2005) (Krug et al., 2004) 
(Tabeta et al., 2004). A study by Zucchini et al suggested an overlapping function for 
TLR7 and TLR9 in the detection of MCMV. Higher susceptibility to MCMV-induced 
death, increased viral load in the spleen and significa tly lower serum levels of IFNα 
were found in TLR9-/-TLR7-/- double knock-out mice in comparison to TLR9 or TLR7 
single knock-out animals. Indeed, the phenotype of TLR9-/-TLR7-/- animals with 
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regards to susceptibility to MCMV-induced death recapitulated that of MyD88-/- mice 
(Zucchini et al., 2008).   
 
HCMV and MCMV infect monocytes and macrophages both in-vivo and in-vitro, with 
permissiveness to infection depending on cellular differentiation state (such that non-
productive versus productive replication is supported in monocytes and macrophages, 
respectively) (Mocarski, 2006) (L.K.Hanson, 2006). Infection of 
monocytes/macrophages by CMVs is considered to play a key role in viral 
dissemination during acute infection, potentially through tissue infiltration of non-
actively infected monocytes followed by differentiation into macrophage thus 
stimulating productive infection and viral spread (Collins et al., 1994) (Stoddart et al., 
1994) (Hanson et al., 1999) (Smith et al., 2004) (Mocarski, 2006). Macrophages, 
monocytes and their progenitor cells have also been implicated as a site of latency 
(Reddehase et al., 2002).  
 
In previous chapters MCMV, and more specifically MCV protein M45, were shown to 
modulate IL-1β-induced IκBα degradation. Following binding of their cognate ligands 
TLR9, TLR7 and the IL-1β receptor induce a largely overlapping MyD88-dependent 
pathway leading to IκBα degradation and NF-κB activation. It would therefore be 
expected that M45 inhibits TLR9- and TLR7- induced NF-κB activation. As outlined 
above, TLR9 and TLR7 have previously been shown to play a role in MCMV detection 
and initiation of anti-viral immune responses. TLR7 and TLR9 are not expressed by 
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fibroblasts in which experiments shown in the previous chapters were performed. 
However, Bone marrow-derived macrophages (BMDM) have previously been found to 
constitutively express TLR7. In addition, TLR9 was found to be expressed at low levels 
in resting BMDM and to be upregulated upon MCMV infection (P.Lacaze, Division of 
Pathway Medicine, Personal communication). Importantly, as discussed above, 
macrophages are considered to play a key role in CMV pathogenesis. Considering the 
roles of TLR7, TLR9 and macrophages in CMV biology it is of interest to examine 
whether, as suggested above, M45 indeed inhibits TLR9- and TLR7- induced NF-κB 






5.2 Results  
 
5.2.1 TLR7 and TLR9-induced IκBα degradation is inhibited in MCMV infected 
BMDM  
 
In previous chapters MCMV was shown to modulate IL-1β-induced IκBα degradation. 
As TLR7/9 utilise a signalling pathway largely overlapping that of IL-1β leading to 
IκBα degradation, it was asked whether MCMV also modulates TLR7/9-mediated IκBα 
degradation in BMDM. Initial experiments tested viral modulation of TLR7-induced 
IκBα degradation since, as mentioned above, TLR7 has previously been found to be 
constitutively expressed in the BMDM model used here. BMDM were mock-treated or 
infected with MCMV, ∆M45 or CM45. At 8 hpi mock-treated and infected cells were 
stimulated with the TLR7 ligand R-848. Whole cell lysates were collected at 0, 10, 30 
and 60 min post stimulation and analysed by Western blotting (Figure 5.1a). In mock-
infected cells treated with R-848, IκBα levels decreased rapidly and were nearly 
abolished (to ~ 5% of IκBα levels in non-stimulated cells) by 30 min post-trea ment. At 
60 min post-stimulation IκBα levels were restored to ~ 77% of levels in non-stimulated 
cells. In contrast, in MCMV infected cells treated with R-848 only a very small decrease 
in IκBα levels, to ~ 88% of those in non-treated cells, was seen at 30 min post 
stimulation. This was followed by recovery to pre-stimulation levels by 60 min post 
treatment. The IκBα degradation profile following TLR7 stimulation of ∆M45 infected 
cells paralleled that seen in non-infected cells. R-848 stimulation of CM45 infected cells 
resulted in a marked decrease in IκBα levels (~ 28% of IκBα amount measured in non-
stimulated cells at 30 min post treatment), followed by an increase in IκBα levels at 
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60 min post treatment (~ 72% of IκBα amount measured in non-stimulated cells). Thus 
the CM45 virus exhibited an intermediate phenotype between wild-type and ∆M45 
viruses (for example, at 30 min post R-848 treatmen IκBα levels in CM45 infected cells 
were lower than those in wild-type virus infected cells but higher in comparison to 





















Figure 5.1: MCMV modulates I κBα degradation following TLR7 stimulation. 
a) BMDM were mock infected or infected with MCMV, ∆M45 or CM45 (MOI =3). 
At 8 hpi cells were stimulated with R-848 (0.1 µM) for the indicated periods of 
time. Whole cell lysates were harvested and analysed by using SDS-PAGE and 
immunoblotting with primary antibodies against IκBα, IE1 or β-Actin. Integrated 
fluorescence intensity was calculated (see Chapter 2 section 2.5.3.2) for IκBα 
protein bands, normalised to corresponding β-Actin levels and expressed as 
percentage of IκBα at min 0 (n = 3).b) BMDM were mock infected or infected 
with MCMV, ∆M45 or CM45 (MOI = 3). At 8 hpi cell viability was determined 
using the Cell Titer-Blue assay and is expressed as percentage of fluorescent 
signal in comparison to mock infected cells. Data is representative of at least 
two experiments (each experiment included 6 replicates, mean values and 
standard error (SE) bars shown) (n = 2).   
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Infection equivalency, examined by measuring IE1 expr ssion, showed IE1 levels in 
∆M45 and CM45 infected cells to be ~ 55% and ~ 75% that of wild type-virus infected 
cells, respectively. One possible reason for the low IE1 expression measured in ∆M45-
infected cultures is that M45 deletion mutants have pr viously been found to grow 
poorly on a macrophage cell line, presumably due to failure to inhibit virus-induced cell 
death (Brune et al., 2001). Hence cell viability following infection with the wild type, 
∆M45 or CM45 viruses was evaluated (Figure 5.1b). Cell viability of infected BMDM 
was found comparable between the three viruses. It is noteworthy that, IκBα levels, at 30 
min post-stimulation, adjusted to IE1 expression are ~ 88, 17 and 37% in wild-type, 
∆M45 and CM45 infected cultures, respectively. Hence, differences in infection 
equivalency alone, as indicated by IE1 expression, are unlikely to explain the different 
competencies of the wild-type, ∆M45 and CM45 viruses to inhibit TLR7-induced IκBα 
degradation. Overall, these data show a strong inhibition of TLR7-induced IκBα 
degradation by MCMV in BMDM.  
 
 
Next it was tested whether MCMV infection modulates TLR9-induced IκBα 
degradation. BMDM were mock treated or infected with MCMV and at 8 hpi stimulated 
with TLR9 the ligand ODN 1668. Whole cell lysates were collected at 0, 10, 30 and 60 
min post stimulation and analysed by Western blotting (Figure 5.2). Stimulation of mock 
infected cells resulted in IκBα levels falling to ~ 38% and ~ 34% of pre-treated lvels 
within 30 and 60 min, respectively. Stimulation of MCMV infected cells resulted in a 
markedly smaller decrease in IκBα levels to ~ 70% and 60% of pre-treated levels at 30 
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and 60 min post-treatment, respectively. These data indicate that MCMV inhibits TLR9, 















Figure 5.2: MCMV modulates I κBα degradation following TLR9 stimulation.  
BMDM were mock infected or infected with MCMV (MOI = 3). At 8 hpi cells were 
stimulated with TLR9 ligand ODN 1668 (1 µM) for the indicated periods of time. 
Whole cell lysates were analysed by using SDS-PAGE and immunoblotting with 
primary antibodies against IκBα or β-Actin. Integrated fluorescence intensity was 
calculated (see Chapter 2 section 2.5.3.2) for IκBα protein bands, normalised to 
corresponding β-Actin levels and expressed as percentage of IκBα at min 0 






5.2.2 TLR7 and TLR9 induced NF-κB nuclear translocation is inhibited in 
MCMV infected BMDM  
 
Results presented in the previous section show that TLR7- and TLR9-induced IκBα 
degradation is inhibited in MCMV infected cells. IκBα sequesters NF-κB in the 
cytoplasm, and stimulation induced degradation of IκBα leads to NF-κB translocation 
into the nucleus. It was therefore asked whether MCMV infection of BMDM inhibits 
TLR7/9-induced NF-κB nuclear translocation. Initially, TLR7 induced NF-κB nuclear 
translocation in MCMV infected cells was examined. BMDM were mock-infected or 
infected with MCMV, and stimulated with TLR7-ligand R-848 before subcellular 
localization of NF-κB was analyzed by immunofluorescence (Figure 5.3a). Prior to 
stimulation of mock-infected or infected cells NF-κB localized to the cytoplasm. As 
expected, R-848 stimulation of mock infected cells re ulted in NF-κB translocation to 
the nucleus. In contrast, NF-κB was retained in the cytoplasm of infected cells fo lowing 
stimulation. Next, the subcellular localization of NF-κB was examined in cells 
stimulated with either a TLR7 agonist (Figure 5.3b) or TLR9 agonist (Figure 5.3c) 
following mock infection or infection with wild type, ∆M45 or CM45 viruses (note that 
in figure sections 5.3b and 5.3c NF-κB and IE1 staining differs from that presented in 
section 5.3a). Mock-infected, ∆M45- or CM45-infected cells stimulated with TLR7 
agonist all exhibited nuclear localization of NF-κB. As described above, TLR7 
stimulation did not result in NF-κB nuclear translocation in wild-type virus infected 
cells. As with TLR7, mock-infected cells responded to TLR9 stimulation by re-
localizing NF-κB to the nucleus, while infection with in wild-type MCMV restricted 
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NF-κB to the cytoplasm. In contrast, in cells infected with ∆M45 or CM45 followed by 
TLR9 stimulation, NF-κB localized to the nucleus. Overall, these results suggest that 

















Figure 5.3: TLR7 and TLR9 induced NF- κB nuclear translocation is 
inhibited in MCMV infected BMDM. a) BMDM were mock infected or infected 
with MCMV (MOI = 1). At 8 hpi cells were mock treated or stimulated with R-848 
(0.1 µM) for 30 min. Cell were then fixed and subcellular localization of NF-κB 
p65 subunit was analyzed by confocal immunofluorescence. b + c) BMDM were 
mock infected or infected with MCMV, ∆M45 or CM45 (MOI = 1). At 8 hpi cells 
were stimulated with R-848 (0.1 µM) (b) or ODN 1668 (1 µM) (c) for 30 min. 
Cells were then fixed and subcellular localization of NF-κB p65 subunit was 


































































































5.2.3 TLR7-induced cytokine secretion in inhibited in MCMV-infected BMDM 
 
Results presented in the previous sections show that TLR7-induced IκBα degradation as 
well as NF-κB nuclear translocation are inhibited in MCMV infect d cells. It was 
therefore tested whether these observations correlate with inhibition of NF-κB 
upregulation of cytokine expression. BMDM were mock infected or infected with 
MCMV, ∆M45 or CM45.  Cells were then stimulated with TLR7 ligand R-848, 
supernatants were harvested and the concentrations of IL-6 and TNFα determined by 
ELISA (Figure 5.4). Wild-type virus or CM45 infected cells stimulated with R-848 
secreted less IL-6 and TNFα than mock infected cells stimulated in the same manner. 
Cells infected with ∆M45 and treated with R-848 secreted more IL-6 and TNFα than 
wild-type virus or CM45 infected cells stimulated in the same manner. Overall, a trend 
towards reduced cytokine secretion was observed in MCMV infected cells treated with 
























Figure 5.4: TLR7-induced cytokine secretion in inhi bited in MCMV-infected 
BMDM. BMDM were mock-infected or infected with MCMV, ∆M45 or CM45 
(MOI = 3). At 8 hpi cells were stimulated with the TLR7 ligand R-848 (0.1 µM). 
After 16 h of stimulation supernatants were harvested and the concentrations of 
IL-6 and TNFα determined by ELISA (Data from two experiments performed is 
shown; each experiment included 3 replicates, mean values and standard error 





5.3 Discussion  
 
Results presented in this chapter show that TLR7- and TLR9-induced IκBα degradation 
and NF-κB nuclear translocation as well as TLR7 mediated upregulation of IL-6 and 
TNFα secretion are modulated in MCMV infected BMDM.  
 
Firstly, TLR7- and TLR9-induced IκBα degradation was shown to be curbed in MCMV 
infected cells (Figures 5.1 and 5.2). This inhibitory effect was stronger in the case of 
TLR7 (with peak IκBα degradation of 5% versus 88% in non-infected and infected cells, 
respectively (Figure 5.1)) in comparison to TLR9 (with peak IκBα degradation of 34% 
versus 64% in non-infected and infected cells, respectively (Figure 5.2)). The reason for 
this is unclear, however one possible explanation is that it results from inherent, i.e. 
independent of infection, variations in TLR7 and TLR9 induced IκBα degradation 
kinetics. In non-infected cells, TLR7 stimulation leads to a rapid and almost complete 
IκBα degradation, whereas TLR9 stimulation results in a slightly delayed and less 
exhaustive IκBα degradation (Figures 5.1 and 5.2). These observations are compatible 
with published data on IκBα degradation following TLR7/9 stimulation in BMDM (Wan 
et al., 2011). It is noteworthy that the agonists used (R-848 and ODN 1668 for TLR7 and 
TLR9, respectively) are commonly used and adequately characterised specific ligands of 
TLR7 and TLR9. Moreover, these ligands have previously been shown to induce NF-κB 
activation and cytokine secretion in macrophages (Hemmi et al., 2000) (Hemmi et al., 
2002) (Heil et al., 2004). Indeed, a central question in NF-κB research is to understand 
the mechanisms controlling the subtle variation in NF-κB activation profiles induced by 
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various receptors including different TLRs (Sen andSmale, 2010) (Bode et al., 2009). In 
turn, it would be of interest to explore viral-host interactions in this context.  
 
Secondly, TLR7 and TLR9 induced NF-κB nuclear translocation was shown to be 
inhibited in MCMV infected cells (Figures 5.3a and 5.3c). These results are in full 
agreement with the observed inhibition of IκBα degradation.  
 
Thirdly, MCMV infected cells treated with a TLR7 agonist were found to secrete less 
IL-6 and TNFα than non-infected cells equally stimulated (Figure 5.4). Cytokine 
secretion in the absence of TLR7 stimulation was not measured. However, it has been 
previously shown that resting BMDM secrete no detectable amounts of IL-6 and TNFα 
and that secretion of these cytokines is upregulated upon infection (Dr P.Lacaze, DPM, 
Personal communications). In results presented here, in the presence of TLR7 simulation 
MCMV-infected cells secreted less of these cytokines in comparison to mock-infected 
cells, indicating that TLR7-induced secretion of IL-6 and TNFα is curbed in MCMV 
infected BMDM. Taken together, these results suggest that TLR7/9-induced NF-κB 
activation is inhibited during MCMV infection of BMDM.  
 
It is noteworthy that BMDM are semi-permissive to infection (L.K.Hanson, 2006). At 
the MOI used in the experiments presented, namely a MOI = 3, ~ 50 -70% of BMDM 
will be productively infected (assessed by flow cytometry measurements of GFP-
positive cells in a population of MCMV-GFP infected BMDM, M.F.B.N. Hassim, DPM, 
Personal communications). That is, a significant propo tion of cells in infected cultures 
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are non-productively infected. It would therefore be of interest to utilise methods which 
allow for assays of interest to be performed only on the infected portion of the cell 
population, these include: - immunofluorescence analysis (as shown above); - flow 
cytometry combined with infection with GFP expressing viruses or staining for a viral 
protein thus allowing gating of infected cells and measurement (by a second staining) of, 
for example, a protein of interest within this selected population; - similarly 
Fluorescence-Activated Cell Sorting (FACS) combined with infection with GFP 
expressing viruses or staining for a viral protein could be used to isolate productively 
infected cells to be assayed in a chosen downstream application.  
 
The role of the MCMV protein M45 in mediating the above shown inhibition of 
TLR7/9-induced NF-κB activation in infected cells was also examined. TLR7-induced 
IκBα degradation, NF-κB nuclear translocation and cytokine secretion in ∆M45 infected 
cells was found comparable to that observed in mock infected cells (Figures 5.1-5.4). 
However interpretation of these results is confounded by the following factors:  
 
1) In experiments examining the modulation of IκBα degradation, IE1 expression, used 
as an indicator of infection, was considerably lower in ∆M45-infected cultures in 
comparison to wild-type virus-infected cells. It is therefore possible that the seemingly 
different ability of the two viruses (wild type and ∆M45) to inhibit TLR7 induced IκBα 
degradation, is at least partially due to varying ifection levels. M45 deletion mutants 
have previously been shown to grow poorly on a macrophage cell line, presumably due 
to failure to inhibit virus-induced cell death, at least in a proportion of the cells, in the 
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absence of M45 (Brune et al., 2001). This might contribute to the low IE1 expression 
observed in ∆M45 infected cultures. Preliminary examination of cell viability following 
infection with wild-type virus and ∆M45 was conducted with no difference in cell 
viability between cells infected with the two viruses observed (Figure 5.1). However, 
this should be further examined using additional methods for assessment of cell viability 
and cell death. Furthermore, additional testing of infection equivalency is required as 
well as examination of the relationship between anysuch variation and the differing 
IκBα degradation profiles measured. Alternatively, techniques which allow examination 
of IκBα levels, or NF-κB function for that matter, at a single cell level (as opposed to the 
cell population view given by Western blotting) should be used in future work. One 
example for this is immunofluorescence analysis of NF-κB subcellular localisation as 
presented in Figure 5.3. Interestingly, in ∆M45 infected cells treated with TLR7/9 
agonists, NF-κB was localised in the nucleus, in contrast to the cytoplasmic localisation 
seen in wild-type virus infected cells. This result indicates a role for M45 in inhibition of 
NF-κB nuclear translocation.  
 
2) The phenotype exhibited by the CM45 virus did not fully replicate the phenotype of 
the wild-type virus. In cells infected with CM45, IκBα degradation following TLR7 
stimulation was only partially inhibited, while an almost complete inhibition of this 
response was observed in wild type virus infected clls (Figure 5.1). This differs from 
observations made in fibroblast cells (Chapter 4) where inhibition of IL-1β-induced 
IκBα degradation was comparable in wild type virus and CM45 infected cells. In this 
regards it should be noted that the M45 gene is expressed in the CM45 virus from a 
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different locus than in the wild-type virus (Jurak nd Brune, 2006) (Mack et al., 2008). It 
is possible that resulting subtle variations, for example, in expression levels of M45 lead 
to functional differences between wild type and CM45, which are more apparent in 
some cell types (macrophages) than in others (fibroblasts). It would be of interest to 
construct a ∆M45 revertant virus in which deleted sequences are reintroduced in the 
correct genomic context, and examine its function in experiments such as the ones 
presented here. Additionally, regardless of the comparison to the wild type virus, the 
function of the CM45 virus in the experiments conducted was somewhat complex. The 
CM45 virus seemed not to or only partially inhibit TLR7 induced IκBα degradation and 
NF-κB nuclear translocation. However, cytokine secretion from CM45 infected cells 
stimulated with a TLR7 ligand was comparable to that observed in wild type infected 
cells (Figures 5.1-5.3). The reason for this discrepancy is not clear. One possibility is 
that the partial inhibition of IκBα degradation, measured in Western blot analysis, wa 
not clearly appreciable (i.e. visible) in the immunofluorescence analysis of NF-κB 
subcellular localisation (that is, NF-κB nuclear translocation in CM45 infected cells 
stimulated with TLR7/9 agonists seems complete althoug  a small but potentially 
significant proportion of NF-κB remained cytoplasmic). In turn it is conceivable that 
even a partial inhibition of NF-κB activation results in markedly dampened upregulation 
of cytokine secretion. To conclude, some indications exist to suggest a role for M45 in 
modulation of TLR7/9 activation of NF-κB in BMDM, however further investigations 




Overall, data presented in this chapter show that TLR7/9-induced NF-κB activation is 
inhibited in MCMV infected BMDM. Experiments present d here used exogenous 
stimulation of TLR7/9 i.e. addition of TLR7/9 ligands to infected cells. Future research 
should examine the significance of this observation in the context of infection induced 








6 Chapter 6 
 
Concluding discussion  
 
CMVs, like all viruses, are obligate parasites which have evolved to harness host cellular 
processes to drive viral replication. However, to be a le to replicate, disseminate and, in 
the case of CMVs, establish latent infection these viruses must contend with host 
defence mechanisms. These include intrinsic cellular defences as well as innate and 
adaptive immune responses. Co-evolution of CMVs with their hosts has allowed these 
viruses to develop an extensive range of strategies to vade, subvert and manipulate the 
host immune response (Mocarski, 2002) (Loewendorf and Benedict, 2010). 
Understanding viral mechanisms of immune modulation is crucial to our understanding 
of pathogenesis, may enhance future therapeutic strategies and can teach us valuable 
lessons about the host response itself.  
 
The key role played by pattern recognition receptors (PRRs) in initiating and shaping the 
host response to infection in general and CMVs in particular is now recognised. Multiple 
PRRs have been implicated in sensing CMVs including TLR-family members TLR2, 
TLR7 and TLR9. NF-κB and MAPK activation pathways utilised by these receptors 
largely overlap signalling cascades induced by the key pro-inflammatory cytokine IL-1β. 
While activation of NF-κB and MAPKs by TLRs and IL-1β is well characterised, little 
is known about the modulation of these signalling events during CMV infection. The 
central hypothesis posed for this thesis was that a viral counter-measure by MCMV 
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involves specific targeting of TLR- and IL-1β-induced signalling along the MyD88 to 
NF-κB pathway.  
 
To begin addressing this hypothesis, it was asked whether MCMV infection modulates 
IL-1β-induced signalling along the MyD88 to NF-κB pathway, more specifically, 
experiments were conducted to evaluate IL-1β-induced degradation of IκBα, the 
hallmark of NF-κB activation, in MCMV infected cells. It was found that IL-1β-induced 
IκBα degradation is, indeed, inhibited in MCMV infected cells in a manner dependent 
on de-novo viral protein expression (Chapter 3). These observations are in agreement 
with the central hypothesis in that IL-1β-induced NF-κB activation (as least as far as 
indicated by IκBα degradation) is inhibited following MCMV infection. Moreover, the 
requirement for de-novo viral gene expression strongly suggests that the observed 
inhibition is, as hypothesised, a result of a viral function and not part of the cellular 
response to infection.  
 
Importantly the above discussed results do not address two key elements in the 
hypothesis. a) It was hypothesised that the IL-1β to NF-κB signalling pathway is 
modulated during infection as a result of specific viral function. To confirm this element 
of the hypothesis evidence needed to be provided showing that the observed inhibition 
of IκBα degradation is a result of a viral mechanism for mdulating cellular signalling, 
and not part of the cell’s own response to infection. The requirement for de-novo viral 
gene expression did imply viral targeting of cellular responses. However, it could not 
have been excluded that IκBα degradation is inhibited in productively infected cells and 
not in non-productively infected cells due to cellular responses initiated by productive 
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but not abortive infection. b) It was hypothesised that MCMV specifically targets IL-1β-
induced signalling. However, it has not been elucidate  whether the observed inhibition 
of IκBα degradation is a result of a specific block in IL-1β signalling or rather a general 
inhibition of IκBα degradation regardless of the initiating signal. To address these 
questions several lines of investigation were possible, ncluding: 1) Identification of the 
viral product/s mediating the observed effect, thus addressing article (a) above; 2) 
Identification of the cellular signalling event targeted by the virus leading to inhibition 
of IκBα degradation, thus addressing article (b) above.  
 
In accordance with this, investigations next focused on determining which viral product 
mediated the observed inhibition of NF-κB activation. This led to the identification of 
viral protein M45 as the viral protein modulating the degradation of IκBα following 
IL-1β stimulation (Chapter 4). Importantly, this represent  a potential novel function of 
this protein. Moreover, this finding proves that the observed inhibition of IL-1β-induced 
IκBα degradation in MCMV-infected cells is, as hypothesis d, a result of a viral 
function.  
 
Research then turned to begin elucidating which signalling event/s in the IL-1β pathway 
is targeted by M45. This was done by examining whether p38 as well as NF-κB 
activation is modulated by M45. IL-1β binding to its receptor induces, via IRAKs and 
TRAF6, the activation of TAK1. At this point the signalling pathway bifurcates as 
TAK1 activates the IKK complex followed by NF-κB, as well as phosphorylates MAPK 
kinases resulting in p38 phosphorylation/activation. Therefore M45 modulation of a 
signalling event upstream or at TAK1 activation would be expected to result in 
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inhibition of activation of both NF-κB and MAPK kinases, whereas M45 modulation of 
a signalling event downstream of TAK1 activation would be expected to result in 
inhibition of NF-κB but not MAPK kinases. Thus through examining whether M45 
perturbs only one or both arms of the pathway it was possible to begin dissecting which 
part of the IL-1β pathway is modulated by M45, as a first step toward identification of 
specific IL-1β-induced signalling events modulated by this protein. Interestingly, it was 
found that IL-1β-induced p38 phosphorylation is not modulated by M45 or by MCMV 
infection for that matter (Chapter 4). As outlined above, this suggests that M45 interferes 
with a signalling event downstream of TAK1 activation i.e. the function of NF-κB and 
its immediate regulatory circuit. Possible points of viral interference include: inhibition 
of TAK1 phosphorylation of the IKK complex, modulation of the IKK complex itself 
(for example, the abundance of IKKα, IKKβ, IKKγ) or its activity (for example, 
blockage of kinase functions) or interference with IκBα processing for degradation. As 
multiple signalling pathways converge at this level of NF-κB activation, this result 
implies that M45 functions to employ a general block n NF-κB activation. That is to 
say, that in contrast to the original hypothesis, M45 does not specifically target the IL-1β 
pathway (as discussed further below).  
 
Finally, research efforts were extended to include TLR signalling, more specifically, 
TLR7/9 signalling in the context of MCMV infection of BMDM. It was shown that, in 
agreement with data presented for IL-1β, TLR7/9-induced NF-κB activation is curbed in 
MCMV infected cells (Chapter 5). Furthermore, viral protein M45 was indicated to 




Overall, data presented in this thesis indicate a previously unrecognised MCMV 
inhibition of NF-κB activation mediated by MCMV protein M45. This research began 
with the hypothesis that MCMV specifically targets TLR- and IL-1β-induced signalling 
along the MyD88 to NF-κB pathway. MCMV, more specifically MCMV protein M45, 
was indeed shown to modulate TLR- and IL-1β-induced NF-κB activation. Initial 
studies suggest that this is due to a viral block of NF-κB activation independently of the 
nature of the stimulus provided. This is in contrast to the original hypothesis, which 
predicted viral modulation of signalling events unique to the TLR- and IL-1β- NF-κB 
activation pathway. Further research is required into the arising hypothesis that - 
MCMV, more specifically MCMV protein M45, inhibits NF-κB activation by targeting 
its immediate regulatory circuit i.e. the function f the IKK complex and IκB proteins. 
Experiments to test this hypothesis could begin with the following: - Examining NF-κB 
activation in MCMV infected cells, or cells expressing M45, in response a range of 
stimuli which utilise various signalling pathways prior to conversion on the TAK1-IKK- 
IκB regulatory subunit (although care should be taken when choosing stimulating 
compounds and with interpretation of such experiments as M45 has previously been 
shown to inhibit signalling, including NF-κB activation, by RIP family members and 
thus pathways utilising RIP proteins). – Examination of the abundance and 
phosphorylation state of IKK complex subunits and IκB proteins in non-treated versus 
M45 expressing cells (whether through infection or transfection), in presences or 
absence of stimulation. - Examination of whether M45 directly binds to IKK complex 
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subunits and IκB proteins. The results of such experiments will then determine further 
research aimed at proving/disproving the above hypothesis.  
 
If the above hypothesis is proven correct, that is M45 is unequivocally shown to inhibit 
NF-κB, the greater question presenting itself would be - what is the role of M45 
inhibition of NF-κB activation in the life cycle of MCMV in vitro? Furthermore, what is 
the role of this M45 function in vivo i.e. its contribution to pathogenesis? As discussed 
in Chapter 4, M45 is known to inhibit the function f RIP3 and as a result prevents the 
infected cell from executing RIP3-dependent cell death. Moreover, there is evidence to 
suggest that M45 interaction with RIP3 is key to in vivo viral replication, dissemination 
and pathogenesis. Importantly, a RHIM domain has been found to mediate the M45-
RIP3 interaction (Upton et al., 2010). Crucial to future research into M45 will be the 
identification of the precise protein domain/s underlying its inhibition of NF-κB activity. 
If the M45 domain required for inhibition of M45 activity is different for that required 
for interaction with RIP3, it would be possible to separate the two functions by creating 
mutant viruses with deletions targeting a specific domain and therefore function of M45. 
This will make it possible to study the in vivo role of NF-κB inhibition by M45 without 
it being confounded with the in vivo role played by M45 interaction with RIP3. It should 
be noted that this experiments would have to be design d and interpreted with care as it 
possible that M45 has additional functions yet to be discovered.  
 
Moreover, it would be of interest to examine the function of M45 throughout the life 
cycle of MCMV. Research work presented here concentrated on a single time point 
(7-8 hpi), however M45 expression in infected cells begins at about 6 hpi and increases 
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thereafter throughout infection. The following question thus arises: are known M45 
functions (inhibition of NF-κB activation, as suggested here, and the previously shown 
modulation of the function of RIP proteins) maintaied throughout infection? Does M45 
gain, lose or has its functions modified as the enviro ment in the infected cell changes 
(for example, as the expression of yet to be identifi d cellular and viral protein 
interaction partners of M45 is up or down regulated)?  
 
It should also be considered that the central hypothesis for this thesis, namely that 
MCMV specifically targets TLR- and IL-1β-induced NF-κB activation, requires further 
examination at times of infection not studied in the work presented here. At the time 
point examined in this thesis viral inhibition of IL-1β-induced NF-κB activation was 
shown to be M45 dependent. However, it is possible that the TLR- and IL-1β-induced 
NF-κB activation is targeted at earlier or later times po t infection by a viral product not 
expressed in the time frame examined in presented experiments. It would be of interest 
to further study TLR- and IL-1β-induced NF-κB throughout MCMV infection using a 
M45 deletion mutant.   
 
During work on this thesis it became apparent that similar work was being undertaken 
by Patricia M. Fliss under the supervision of Prof. Wolfram Brune (Heinrich Pette 
Institute, Hamburg, Germany). Their research agrees with the findings of this thesis i.e. 
that M45 inhibits IL-1β- and TLR-induced NF-κB activation. Furthermore, it confirms 
that, as hypothesised above, this is achieved by M45 disruption of the NF-κB-regulatory 
module. More specifically, M45 was found to bind to the IKKγ (NEMO) subunit of the 
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IKK complex, leading to the re-direction of IKKγ to autophagosomes for subsequent 
degradation in lysosomes (Fliss et al., 2012). 
 
Considering the key role played by NF-κB in mediating intra-cellular- and immune- 
responses to infection surprisingly little is known about how NF-κB function is 
modulated by MCMV, or by HCMV for that matter. This study and crucially the 
identification of the specific viral protein, namely M45, modulating the function of this 
key transcription factor significantly improves and expands current knowledge regarding 
CMV- NF-κB interplay. That said the key importance of these finding is that they can 
serve to assist the dissecting of the role of NF-κB controlled host responses in 
controlling infection. Moreover, this work together with previous studies identifies M45 
as crucial mediator of viral pathogenesis. Thus M45 is marked as a specific target for 
drug design. Indeed, the ultimate challenge is to translate the insights provided by such 
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